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Viperin (Virus Inhibitory Protein; Endoplasmic Reticulum associated, INterferon 
inducible) is an endoplasmic reticulum (ER)-associated antiviral responsive protein 
that is highly up regulated in eukaryotic cells upon viral infection. Viperin is a radical 
S-adenosyl-L-methionine (SAM) enzyme, that catalyses the synthesis of antiviral 
nucleotide 3’-deoxy-3’, 4’-didehydro-CTP (ddhCTP) exploiting radical SAM chemistry. 
However, the modulation of its catalytic activity by other intracellular proteins is not 
well understood and needs further investigation. In this dissertation, I use enzymology-
based approaches to investigate how viperin’s enzymatic activity is regulated through 
its interaction with various cellular and viral proteins that are involved in cellular 
metabolic and signalling pathways and viral replication. I showed that viperin can 
reduce the intracellular expression level of the cholesterol biosynthetic enzyme, 
farnesyl pyrophosphate synthase (FPPS). This, in turn perturbing the intracellular 
cholesterol synthesis, thereby retarding budding of enveloped viruses from 
cholesterol-rich lipid rafts of host cell membranes. I also undertook a proteomics study 
that revealed that viperin interacts with several other endogenous cholesterol 
biosynthetic enzymes. I also demonstrated that viperin promotes the degradation of 
viral non-structural protein A (NS5A) from hepatitis C virus through proteasome-
mediated degradation in the presence of sterol-regulatory protein VAP-33. In turn, co-
expression of viperin with VAP-33 and NS5A reduced the specific activity of viperin by 
~ 3-fold. Lastly, this study showed that viperin is activated by innate immune signalling 
proteins kinase IRAK1 and ubiquitin ligase TRAF6, as it facilitates the ubiquitination of 
xx 
 
IRAK1 by TRAF6. The results provide valuable insights into the mechanism of action 






Introduction: The Radical S-adenosylmethionine Enzyme Viperin 
is an Anti-viral Responsive Protein  
 
 1.1 Overview of radical enzymes: Many enzymatic reactions proceed through 
mechanisms involving free radical intermediates. Enzymes use the reactivity of the 
unpaired electron to overcome the energy barrier in chemically challenging reactions.  
Radical-based reactions in enzymology are often associated with redox-active (flavin, 
quinone, pterin) (1-9) or metal-based (cobalamin, heme, non-heme, mononuclear copper) 
(1,9-18) cofactors. The importance of 5-’deoxyadenosyl radical in biological 
transformations has gained attention due to its ability to catalyze a diverse range of 
reactions. The two classes of enzymes generate 5’-deoxyadenosyl radical as a part of 
their mechanism. Adenosylcobalamin (AdoCbl) and radical S-adenosylmethionine 
(AdoMet) dependent enzymes initiate the free radical chemistry by generating 5’-
deoxyadenosyl radical either by homolytic cleavage of adenosylcobalamin or single‐
electron reduction of S‐adenosylmethionine (AdoMet), respectively [Figure 1.1]. 
Although both of these classes of enzymes perform similar chemistry, the Radical SAM 
enzymes use a cofactor that is much simpler to synthesize, with less complicated 
biosynthetic and transport machinery. With the addition of new enzymes to this 
superfamily, Radical SAM enzymes are the subject of extensive research to understand 





Figure 1.1: Generation of 5’-deoxyadenosyl radical by Adenosylcobalamine (AdoCbl) 
and S-adenosylmethionine (AdoMet) superfamily of enzymes. Figure reproduced from J. 
Am. Chem. Soc. 2019, 141, 30, 12139-12146 (20) 
 
 
1.2 Introduction to radical SAM enzymes: The Radical S-adenosyl-L-methionine 
enzymes superfamily (12,21,22) is one of the more recently recognized classes of radical 
enzymes, but also extremely widespread comprising more than 300,000 members. The 
enzymes in the superfamily catalyze a diverse range of chemical reactions, participating 
in numerous biosynthetic pathways, such as cofactor, antibiotics and small molecule 
biosynthesis, DNA repair and metabolism (12,21,22,31,32).  Well-studied examples 
include ribosomal RNA methyltransferases RlmN and Cfr (23,24) (adenine methylation), 
lysine-2,3-amiomutase (25) (isomerization), biotin synthase (26) (sulfur insertion),  
methythiotransferases MiaB, RimO, and MtaB (27) (thiomethyl insertion), molybdopterin 
cofactor biosynthetic enzyme MoaA (28) (cyclization of GTP to molybdopterin precursor), 
protein activating enzymes PFL-AE (29) and aRNR-AE (30) (protein radical generation) 




Figure 1.2: Reactions catalyzed by different radical S-adenosylmethionine superfamily 
of enzymes. (A) Methylation by ribosomal RNA methyltransferase RlmN; (B) 
Isomerisation by lysine-2,3-aminomutase (LAM); (C) Sulfur insertion by biotin synthase 
(BioB); (D) Thiomethylation by methylthiotransferase MiaB; (E) Cyclisation of GTP by 
molybdenum cofactor biosynthesis protein MoaA; (F) Glycyl radical generation by 
pyruvate-formate lysae activating-enzyme (PFL-AE). 
 
 
Despite their functional diversity, these enzymes share some common features (33-35). 
They are characterized by the presence of a conserved CxxxCxxC motif, the cysteines 
chelating three iron atoms of a [4Fe-4S]2+/+ cluster. The cofactor/co-substrate S-adenosyl-
L-methionine (SAM/AdoMet) is directly coordinated to the fourth, unique iron atom of the 
cluster to allow electron transfer during the course of the reaction [Figure 3]. Most of the 
enzymes adopt a partial TIM-barrel structure, comprised of six (β/α) motif [Figure 1.3 
(A)]. The iron-sulfur cluster is bound at the top of the partial β-barrel core domain. The 
AdoMet moiety coordinates the iron-sulfur cluster in a hydrophilic binding site, adopting 









Figure 1.3: Structure of radical SAM enzyme pyruvate-formate lysae activating enzyme 
(PFL-AE) (PDB ID 3CB8). (A) Enzyme adopting a partial TIM-barrel structure, comprising 
of six (β/α) motif; (B) Zoomed in view of the ligand binding site with the iron-sulfur cluster 
(yellow-orange) and S-adesnosyl-Lmethionine cofactor (green), chelated to CxxxCxxC 
signature motif (magenta). 
 
The structural similarity among the radical SAM enzymes allows them to share a common 
reaction mechanism, involving a single-electron reductive cleavage of SAM by the iron-
sulfur cluster and generation of a highly reactive radical intermediate, 5'-deoxyadenosyl 
radical (dAdo.). In the presence of substrate, the radical abstracts a hydrogen atom from 
the substrate and forms 5’-deoxyadenosine (dAdoH) as a by-product [Figure 1.4] (21). 
The substrate radical thus generated undergoes a wide variety of reactions in the 
subsequent steps, dependent on the enzymes. In the absence of the substrate, 
uncoupled turnover can occur, leading to the radical being quenched by the solvent or 




























































Figure 1.4: General reaction mechanism of radical SAM enzymes: one-electron reductive 
cleavage of SAM by the iron-sulfur cluster to generate 5’-deoxyadenosyl radical. The 
radical abstracts hydrogen atom from the substrate of the protein, generating a substrate 
radical and 5’-deoxyadenosine as the by-product. 
 
    
1.3 Viperin (Radical SAM domain-containing protein 2) is a member of the radical 
SAM enzyme superfamily that shows antiviral activity: Investigating the reaction 
mechanisms of radical SAM enzymes is quite challenging due to the oxygen sensitivity 
of the iron-sulfur cluster and the instability of radical intermediates. Although the presence 
of radical SAM enzymes was thought to be confined to anaerobic microorganisms, the 
recent emergence of their importance in human metabolism and signaling pathways 
provides new insights into the function of these enzymes (32).  To date, eight radical SAM 
enzymes have been found in humans: they are involved in molybdenum cofactor 
biosynthesis, fatty acid synthesis, tRNA modifications, and the antiviral response(32). The 
Radical S-adenosylmethionine domain-containing protein 2 (RSAD2) or viperin (virus 
inhibitory protein, endoplasmic reticulum-associated, interferon-inducible) is one enzyme 
(36-42),  that is increasingly receiving attention due to its ability to restrict a broad range 
of viruses, including human cytomegalovirus (HCMV)(44-46), influenza A virus(47), 
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HIV(48), hepatitis C virus(49-51), zika virus(52-54), Encephalitis virus (52,55), and 
Dengue virus (56,57) [Figure 1.5]. The mechanisms by which viperin mitigates viral 
infection appear to be dependent on the identity of the virus and are quite variable in 
nature. It has been shown to interact with numerous cellular and viral proteins. However, 
the involvement of catalytic mechanism of viperin as a radical SAM enzyme while exerting 
antiviral activity by regulating the protein targets lacks proper explanation and needs 
further investigation.  Taking biochemical and cellular biology approaches, my major goal 
in this study is to establish molecular-level insights into the interactions between viperin 
and its cellular targets, while behaving as a radical SAM enzyme. 
 
Figure 1.5: Overview of anti-viral response of viperin: Viperin is up-regulated in the cells 
by innate immune Toll-like receptors (TLR7/9) and it inhibits a broad range of viruses.  
 
In 1997, the mRNA of RSAD2/viperin was first identified as cytomegalovirus-inducible 
gene 5 (cig5) through differential display PCR from a cell culture infected with human 
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cytomegalovirus (HCMV) (58) and later its sequence identity with radical SAM enzyme 
MoaA was confirmed (59). In 2001, the gene was isolated from human cytomegalovirus 
(HCMV) infected fibroblasts (44). When stably expressed, viperin was shown to restrict 
HCMV replication and abolish the expression of structural glycoproteins of the virus, while 
localized to the endoplasmic reticulum. Furthermore, this highly species-conserved 
protein was recognized in various mammals, fish, and reptiles (60).  
Viperin is expressed at a low basal level in most cells and induced by type I, II, III 
interferon, double-stranded DNA and RNA, lipopolysaccharides, Poly I:C and multiple 
viruses(40,59,61,62). Especially, the expression of mammalian viperin is found to be 
induced by interferon-dependent and independent pathways or through direct activation 
of Toll-like-receptor (TLR) or RIG-I-receptors (RLR) by viruses. The interferon-stimulating 
gene factor 3 (ISGF3) shows strong regulation of viperin expression in the interferon-
dependent pathway, whereas its interferon-independent expression is controlled by 
interferon regulatory factors (IRF1 and IRF3)(62). 
1.4: Structure of viperin: Sequence analysis and a recent crystal structure of mouse 
viperin predict that this 361 amino acid protein, with 42 kDa molecular mass, contains 
three distinct domains (36,39-41,63). The N-terminal domain, which shows variability 
between species in length and sequence, has an amphipathic α helix that binds at the 
cytosolic face of the endoplasmic reticulum (ER) and lipid droplets (64-66). In contrast, 
the central SAM-binding domain and C-terminal domain are highly conserved. The central 
domain (71-182) contains a tri-cysteine motif (CxxxCxxC), responsible for binding the 
iron-sulfur cluster. The AdoMet cofactor interacts with a conserved GGE motif and 
arginine 194 and serine 180, observed in this central domain region (63). Although the 
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Fe-S binding motif seems to be essential for viperin’s anti-viral activity against HCV and 
HCMV, the role of this domain has yet to be determined. The C-terminal domain is mostly 
disordered and shown to be crucial in substrate recognition. Studies show that the C-
terminal tryptophan in this domain interacts with CIAO1, a [Fe-S] cluster installing protein. 
Thereby, truncation of C-terminal results in an enzymatically inactive viperin, 
compromising its antiviral activity against HCV, HIV-1 and Dengue virus type-2.  The 
crystal structure of mouse viperin showed that amino acid residues 75-284 adopt a partial 
(βα)6 fold [Figure 1.6 (A)], similar to other radical SAM enzymes; whereas the N-terminal 
(45-73) and last 26 amino acids in the C-terminal (337-362) are disordered.  The C-
terminal extension is flexible and folds over the barrel, mimicking a closed (βα)8 - barrel 
fold (63).  
 
Figure 1.6: Structure of mouse viperin (PDB ID 5VSL): (A) Overall partial TIM barrel folds 
of viperin. The radical SAM domain and the C-terminal domain are shown in blue and red, 
respectively. (B) Zoomed in view of active site, containing the positively charged amino 
acids (Blue), and facing the iron-sulfur cluster (Yellow-orange) binding site, comprised of 
β-sheet and loops from radical SAM domain (green) and C-terminal domain (maroon). 
A close structural similarity has been observed between and viperin and radical SAM 
enzyme MoaA, that catalyze the cyclization of GTP to 3′, 8-cyclic-GTP in the first step of 
molybdenum cofactor biosynthesis. It shows a similar β-barrel fold with a flexible C-
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terminal extension as does viperin [Figure 1.7]. A remarkable structural alignment is 
observed at the second β-strand between these two proteins, bearing the SAM binding 
motif and positively charged and hydrophilic amino acid residues at the active site (Lys69, 
Lys163, Arg192, Thr73, Asn165 in MoaA and Lys120, Lys220, Lys247, Ser124, Asn222 
in viperin) [Figure 1.6 (B)]. From this structural basis, it was predicted that viperin might 
contain a nucleoside-triphosphate binding site and use an NTP as potential substrate 
(36,63). 
 
Figure 1.7: Overlay of crystal structures of viperin (5VSL) in cyan and molybdenum 
cofactor biosynthesis protein MoaA (2FB3) in magenta.  
 
1.5: Prediction of the substrate of viperin: Initially, there was no direct evidence of the 
identity of the substrate of viperin. Numerous biochemical and virological phenomena 
provided indirect evidence regarding the structure or characteristics of the substrate of 
viperin. Overexpression of wild-type human viperin in E.coli showed an elongated 
morphology in E.coli, whereas cells overexpressing a mutant enzyme unable to bind the 
iron-sulfur cluster did not show any morphological change (67). This suggests that viperin 
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utilizes cellular metabolites, common to both bacteria and humans, in a SAM-dependent 
manner; and alter the lipid metabolism and perturb cell-division. Supporting this 
observation, geranyl pyrophosphate (GPP) and farnesyl pyrophosphate (FPP), two 
terpene intermediates in the mevalonate and cholesterol biosynthesis pathway were 
tentatively identified as potential substrates of viperin (68). During SAM- cleavage activity, 
recombinant human viperin showed enhanced production of 5’-deoxyadenosine in the 
presence of these two small molecules, coupled with the incorporation of a 
nonexchangeable hydrogen atom from GPP and FPP in a deuterium oxide exchanged 
buffer solution [Figure 1.8]. However, the biochemical significance of viperin's activity on 
the cholesterol level in the presence of these small molecules remains unexplained.  
 
Figure 1.8: The production of 5’-deoxyadenosine (5’dA) by viperin in the presence of 
different small molecules: Geranyl pyrophosphate (GPP) and Farnesyl pyrophosphate 
(FPP) showed increase in the production of 5’-dA, when assayed with viperin in the 
presence of SAM and dithionite. Figure reproduced from FEBS Lett., 592, 2, 199-208 
Similarly, a nucleoside-sugar was characterized to be a possible small molecule substrate 
of viperin, as viperin interacts with several viral glycoproteins to limit the viral assembly 
and maturation process. In-vitro radical SAM activity of fungal viperin in the presence of 
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uridine diphosphate glucose (UDP-glucose) produced a modified nucleoside-sugar via a 
coupling reaction between UDP-glucose, 5’-deoxyadenosine radical and a hydrogen 
atom from the solvent [Figure 1.9]. These observations support the hypothesis that 
viperin can prevent the formation of oligosaccharide precursors, required for the 
expression of viral glycoproteins; however, direct evidence for viperin's inhibitory activity 
against glycosylation was not studied in this case(69).    
 
Figure 1.9: The addition reaction of a 5′‐dAdo radical and a hydrogen atom to UDP‐
glucose, catalyzed by viperin: (A) A product [M + H] with m/z of 818.1, denoting the 
presence of the addition product,  was detected only in the presence of Viperin, SAM, 
UDP‐glucose, and sodium dithionite (SD). (B) The observed mass matches accurately 
with the predicted mass of the addition product. Figure reproduced from FEBS Lett., 591, 
16, 2394-2405.  
 
Based on the fact that the gene encoding viperin is found adjacent to nucleotide 
monophosphate phosphorylating enzyme cytidylate monophosphate kinase 2 (CMPK2), 
it was predicted that viperin might have similar nucleotide modifying activity. Indeed, 
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recently, rat viperin was shown to catalyze the conversion of cytidine triphosphate to 3′-
deoxy-3′,4′-didehydro-cytidine triphosphate (ddhCTP) in a radical dependent manner, 
both in mammalian cells and in vitro (70).  The 5'-deoxyadenosyl radical generated by 
viperin from reductive cleavage of SAM, abstracts a hydrogen atom from the 4'-carbon of 
CTP forming a substrate radical, which rearranges to ddhCTP [Figure 1.10]. Lacking the 
3'-hydroxyl, this ribonucleotide acts as a viral RNA polymerase chain terminator, for RNA-
depepndent RNA polymerases from flaviviruses such as the Hepatitis C virus, Dengue 
virus, West Nile virus and Zika virus. However, this antiviral nucleotide is not sensitive in 
inhibiting all RNA viruses, suggesting that this is not the general mechanism of viperin to 
exert its antiviral activity (70).  
 
Figure 1.10: The conversation of CTP to 3′-deoxy-3′,4′-didehydro-cytidine triphosphate 
(ddhCTP) by viperin.  
 
1.6: Regulation of cellular and viral proteins by viperin:  Although a direct biochemical 
function of the enzyme activity of viperin was established in this study, its virus-specific 
inhibitory mechanism is not well understood to date. Viperin has been reported to target 
several cellular and viral proteins while modulating metabolic and signaling pathways that 
restrict replication of a broad spectrum of DNA and RNA viruses, including herpesviruses 
(HCMV) (44,45), flaviviruses (HCV, West Nile virus/WNV, Zika virus and Dengue 
























































orthomyxovirus (Influenza A virus) (44,47), paramyxovirus (Sendai virus) (42), and 
rhabdovirus (VSV) (42). Viperin was shown to reduce the human cytomegalovirus 
(HCMV) infection by perturbing the expression of viral structural proteins (gB, pp28, and 
pp65), required for virus maturation and assembly (44,46).  Viperin was also shown to 
interact with both structural and non-structural proteins for several Flaviviridae viruses 
and prevent viral replication in host cells(71).  In fact, the flaviviruses responded differently 
upon viperin induction; for example; the non-structural protein NS3 from the tick-borne 
encephalitis virus (TBEV) and Zika virus (ZIKV) (52), but not from JEV and YFV, was 
shown to interact and be degraded by viperin through the proteasomal-degradation 
pathway(74). In another case, the Dengue virus C protein was shown to interact with 
viperin, but not the TBEV C protein (56,72).  To explain a broader mechanism of inhibition, 
viperin was also shown to inhibit the activity of bacteriophage T7 DNA-dependent RNA 
polymerase, as T7 polymerase is widely used as a model to study transcription (75). 





Figure 1.11: Regulation of different metabolic pathways by viperin through its interaction 
with multiple cellular and viral proteins in vivo, upon viral infection.  
 
 
Apart from viral proteins, viperin is also demonstrated to regulate cellular metabolic and 
signaling pathways, responsible for the progress of virus infection. Viral budding of 
enveloped viruses, e.g, influenza virus, and HIV, from the host cell membrane-associated 
lipid-rafts, was shown to be stalled due to overexpression of viperin, potentially due to its 
regulatory effect on the lipid metabolism during infection. This might be achieved through 
the interaction of viperin and farnesyl pyrophosphate synthase (FPPS), a key enzyme for 
isoprenoid and cholesterol biosynthesis. The inhibition of viral release of the influenza 
virus by viperin was significantly reversed by overexpression of FPPS in HeLa cells(47). 
A similar effect was observed during inhibition of HIV by viperin in macrophages, where 
the addition of exogenous farnesol restored viral egress, consistent with the interaction 
between viperin and FPPS was responsible for this viral-repression [Figure 1.11] (48).   
The importance of viperin as a key regulator in lipid metabolism was also established 
during human cytomegalovirus infection, as viperin was observed to relocalize to 
mitochondria and interact with the mitochondrial trifunctional protein (TFP) beta subunit 
(HADHB) that mediates fatty acid β-oxidation. This protein-protein interaction resulted in 
a decrease in cellular ATP level, in turn, weakening the actin cyto-skeleton to facilitate 
egress of the virus from the cells [Figure 1.11] (45,76).   
In several cases, viperin was described to exert its antiviral activity by regulating protein 
and lipid secretion pathways. The N-terminal amphipathic helix of viperin was observed 
to be responsible for restraining the secretion of soluble proteins, required for ER-to-Golgi 
trafficking (65). Consistent with this observation, an interactome analysis of viperin 
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identified the Golgi brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1), a 
cellular protein involved in ER to Golgi vesicle-mediated transport, as one of its targets 
(72).   
While there is definite proof that viperin can exert antiviral activity over a broad range of 
pathogens, its role in directly modulating innate immune signaling is also recognized. 
Viperin enhanced signal transduction through Toll-like receptors 7 and 9 (TLR7/9) which 
recognize viral nucleic acids and stimulate antiviral effector genes. Viperin was shown to 
interact with interleukin-1 receptor-associated kinase (IRAK1) and tumor necrosis factor 
receptor-associated factor 6 (TRAF6) in the signaling complex on lipid bodies; thereby 
facilitating the ubiquitination of IRAK1 by Ubiquitin ligase protein TRAF6. This, in turn, 
aided the translocation of IRF7 to the nucleus, where the antiviral interferon-stimulated 





Figure 1.12: Viperin directly participate in innate immune signaling pathways by 
interacting with Toll-like receptor proteins IRAK1 and TRAF6 and mediating the 
ubiquitination of IRAK1 by TRAF6.  
 
1.7: Goal of the dissertation research: While structurally and functionally viperin 
behaves as a radical SAM enzyme, it is still unclear how radical SAM chemistry is 
imparting immune system regulation by viperin, as it interacts with cellular and viral 
proteins. To this end, the goal of my dissertation project is to find out how viperin regulates 
its target proteins and thereby plays a role in suppressing metabolic pathways important 
in viral replication. I further aim to determine whether viperin exploits its radical SAM 
activity in regulating its target proteins.   
In this dissertation project, I studied the regulation of two potential protein targets by 
viperin; a cellular protein, farnesyl pyrophosphate synthase (FPPS) and a viral protein, 
non-structural protein (NS5A). Cell-based in vivo and purified protein-based in vitro 
studies were being employed to validate the protein-protein interactions and enzymatic 
activities of viperin and these two targets. Taking a similar experimental approach, the 
modulation of viperin's enzymatic activity through its interaction with two innate immune 
proteins, was also investigated.  Lastly, mass spectrometry-based proteomics analysis 
on immunoprecipitated viperin was also performed to identify other potential binding 
partners that may facilitate complex formation between viperin and its target proteins.  
Moreover, a detailed pathway analysis of the proteomics data revealed which cellular 
pathways viperin is involved. Overall, in this dissertation project, I have focused on 
enzymatic and biochemical approaches to address the mechanism of viperin at the 
molecular level, aiming to resolve a unifying course of action of its seemingly diverse anti-
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viral activity. The involvement of radical SAM chemistry in the mammalian antiviral 
responsive system is unexpected and sets viperin apart from other radical SAM enzymes. 
This study at the interface of immunology and enzymology represents a unique approach 
to understand this enzyme and aims to break new ground in our understanding of the 
innate immune system. 
      
References 
1. Frey, P. A., Hegeman, A. D., and Reed, G. H. (2006) Free Radical Mechanisms in 
Enzymology. Chem. Rev. 106, 3302-3316 
2. Kay, C. W. M., Feicht, R., Schulz, K., Sadewater, P., Sancar, A., Bacher, A., 
Möbius, K., Richter, G., and Weber, S. (1999) EPR, ENDOR, and TRIPLE 
Resonance Spectroscopy on the Neutral Flavin Radical in Escherichia coli DNA 
Photolyase. Biochemistry 38, 16740-16748 
3. Guan, Z.-W., Kamatani, D., Kimura, S., and Iyanagi, T. (2003) Mechanistic Studies 
on the Intramolecular One-electron Transfer between the Two Flavins in the 
Human Neuronal Nitric-oxide Synthase and Inducible Nitric-oxide Synthase Flavin 
Domains. J. Biol. Chem. 278, 30859-30868 
4. Tittmann, K., Wille, G., Golbik, R., Weidner, A., Ghisla, S., and Hübner, G. (2005) 
Radical Phosphate Transfer Mechanism for the Thiamin Diphosphate- and FAD-
Dependent Pyruvate Oxidase from Lactobacillus plantarum. Kinetic Coupling of 
Intercofactor Electron Transfer with Phosphate Transfer to Acetyl-thiamin 
Diphosphate via a Transient FAD Semiquinone/Hydroxyethyl-ThDP Radical Pair. 
Biochemistry 44, 13291-13303 
5. Fitzpatrick, P. F. (1999) Tetrahydropterin-Dependent Amino Acid Hydroxylases. 
Annu. Rev. Biochem. 68, 355-381 
6. Kappock, T. J., and Caradonna, J. P. (1996) Pterin-Dependent Amino Acid 
Hydroxylases. Chem. Rev. 96, 2659-2756 
7. Anthony, C. (2004) The quinoprotein dehydrogenases for methanol and glucose. 
Arch. Biochem. Biophys. 428, 2-9 
8. Davidson, V. L. (2004) Electron transfer in quinoproteins. Arch. Biochem. Biophys. 
428, 32-40 
9. Shibata, N., and Toraya, T. (2015) Molecular architectures and functions of radical 
enzymes and their (re)activating proteins. The Journal of Biochemistry 158, 271-
292 
10. Meunier, B., de Visser, S. P., and Shaik, S. (2004) Mechanism of Oxidation 
Reactions Catalyzed by Cytochrome P450 Enzymes. Chem. Rev. 104, 3947-3980 
18 
 
11. Hiner, A. N. P., Raven, E. L., Thorneley, R. N. F., Garcıá-Cánovas, F., and 
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Probing the Radical SAM Activity of Viperin in Regulating Cellular 
Protein Farnesyl Pyrophosphate Synthase 
 
(Works in this chapter are mostly published in J.Biol. Chem. (2016) 291, 26806-26815.) 
 
 
2.1 Introduction Numerous enveloped viruses exploit lipid rafts in host cell plasma 
membranes for viral assembly and budding from the cell (1-3). Lipid rafts are cholesterol 
and sphingolipid rich micro-domains in the plasma membrane that maintain the fluidity of 
the membranes (3). These rafts provide a platform for viral inner structural proteins to 
bind to the host cell membrane (1). This facilitates various steps in the viral assembly 
process, including the interaction between viral capsid glycoproteins and structural 
proteins, multimerization of internal structural and transmembrane proteins and budding 
and release of viral particles (1,2). Most enveloped viruses and a few non-enveloped 
viruses (e.g Simian virus 40 or SV40)(1) employ lipid rafts in the host cell membrane for 
virus entry, replication, and egress. Depletion of cellular cholesterol levels, using 
cholesterol reducing drugs, such as, lovastatin and gemfibrozil, significantly reduces the 
expression of viral glycoproteins and reduces viral stability and infectivity (4,5). Therefore, 
targeting cholesterol and lipid biosynthesis pathways may be a promising broad-spectrum 
antiviral strategy against enveloped viruses.  
The expression of viperin is an anti-viral strategy taken by the host cell to regulate the 
cellular level of cholesterol [Figure 2.1] (6,7). Viperin was shown to prevent the release
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 of Influenza A virus by down-regulating cholesterol synthesis and perturbing lipid-raft 
formation (6). Viperin mediated inhibition of Human Immuno-deficiency Virus replication 
was reversed in the presence of exogenous farnesol, a precursor of cholesterol synthesis 
(8). Regulation of cellular lipid levels by viperin was also observed during the repression 
of respiratory syncytial virus (RSV) infection, as it disrupted the formation of viral filament 
structure (9). In another study, overexpressed viperin in hamster derived kidney cells 
decreased the level of cholesterol and sphingomyelin in the cell membrane (10).  
The underlying mechanism involved in the regulation of cellular lipid levels by viperin was 
studied by Wang et al (6). Their study showed that viperin binds and inhibits farnesyl 
pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway, that leads to 
synthesis of isoprenoids and sterols. FPPS is a cytoplasmic enzyme that catalyses the 
condensation of geranyl pyrophosphate (GPP) with isopentenyl pyrophosphate (IPP) to 
form farnesyl pyrophosphate, a key intermediate in the biosynthesis of isoprenoids and 
cholesterol (11). Overexpression of viperin in the HeLa cells for 48 hours resulted in a 
reduction of endogenous FPPS activity by 50% (6).  
 
Figure 2.1: Regulation of FPPS by viperin: Reduction of cellular FPPS level can retard cholesterol 
biosynthesis, thereby disrupting formation of lipid rafts and stalling viral budding process.  
 
Given that many enveloped viruses exploit cholesterol-rich lipid rafts in the cell membrane 
during the process of viral budding, it was proposed that inhibiting FPPS (and thereby 
26 
 
inhibiting cholesterol production), viperin can prevent viral release from the infected cell. 
Alternatively, through inhibition of FPPS activity and therefore the production of 
isoprenoid moieties, viperin may be affecting the prenylation state of various cellular 
proteins that are necessary for viral release. In either case, the exact mechanism by which 
viperin inhibits FPPS is still unknown. Also, it was not clear from previous study whether 
viperin acts as a radical SAM enzyme while inhibiting FPPS.  
The goal of this work was to investigate the nature of the inhibitory interaction between 
viperin and FPPS. This work established that viperin reduces FPPS activity by lowering 
the steady-state level of the enzyme within the cell, rather than directly inhibiting its 
catalytic turnover rate. Even though full-length viperin can reductively cleave SAM in a 
slow, uncoupled fashion and produce 5’-deoxyadenosine, this cleavage reaction is 
independent of FPPS. However, at the time of this study, it was not known that CTP is a 
co-substrate of viperin, therefore, the activity of viperin measured here in the absence of 
CTP only reflects the uncoupled reaction. Furthermore, mutation of key cysteinyl residues 
(conserved CxxxCxxC motif) ligating the catalytic [4Fe-4S] cluster in the radical SAM 
domain, surprisingly, does not abolish the inhibitory activity of viperin against FPPS; 
indeed some mutations potentiate viperin activity. Further characterization of viperin 
activity through deletion and substitution experiments showed that the observed decrease 
in the intracellular amount of FPPS is dependent on localization of viperin to the 
endoplasmic reticulum by its native N-terminal amphipathic α-helix. These results were 
done collaboratively with Caitlyn Makins and Gabriel David Román-Meléndez and 




2.2 Results Our initial experiments took a reductive approach and focused on studying 
the interaction of viperin with FPPS using recombinant proteins over-expressed and 
purified from E. coli.  FPPS could be over-expressed and purified from E. coli without 
difficulty and possessed a specific activity similar to that reported in the literature (12).  
Viperin lacking the first 50 residues that comprise the N-terminal the amphipathic helical 
domain (designated viperinΔN50 here) was over-expressed as an N-terminal 6xHis-
tagged construct and purified using standard approaches; similar to those described 
previously (13), inside Coy chamber to minimize exposure to oxygen. The [4Fe-4S] 
cluster could be reconstituted by incubating viperinΔN50 with Na2S, Na2S2O4 and 
Fe(NH3)6SO4 under anaerobic conditions, followed by desalting to remove excess 
reagents. In the presence of dithionite and SAM, the reconstituted enzyme catalyzed the 
slow, uncoupled reductive cleavage of SAM to form 5’-deoxyadenosine as previously 
reported by Duschene and Broderick (13).  Attempts to express the full-length enzyme in 
E. coli proved unsuccessful; for reasons that are unclear no protein expression could be 
detected from cells transformed with the appropriate pET28 expression construct and 
induced with IPTG (25).   
[4Fe-4S]-reconstituted viperinΔN50 and FPPS were incubated together in at equimolar 
concentrations, ~ 10 μM each, (10 mM Tris-Cl buffer, pH 8.0, containing 300 mM NaCl 
and 10% glycerol) in the presence of 5 mM dithionite, 5 mM DTT and 200 μM SAM under 
anaerobic conditions at room temperature for 60 min.  After the incubation period, the 
activity of FPPS was determined under anaerobic conditions using 14C-isopentenyl 
pyrophosphate (IPP) and geranyl-pyrophosphate (GPP) as substrates and following the 
incorporation of radioactivity into farnesyl-pyrophosphate (FPP).  However, despite 
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multiple trials in which the incubation times and temperature were varied around these 
initial conditions, in no change in the activity of FPPS was detected in these experiments.  
Similarly, the presence of FPPS did not stimulate the reductive cleavage of SAM by 
viperinΔN50, as might be expected if FPPS was a substrate for viperin.  This work was 
done collaboratively with Gabriel David Román-Meléndez. 
Faced with these negative results we concluded that either viperin requires the N-terminal 
domain for activity against FPPS and/or those additional cellular components are 
necessary for viperin to interact with FPPS.  We therefore pursued our investigation of 
the effect of viperin on FPPS in a human cell line, HEK293T.  We reasoned that this 
environment should provide: a) the cellular machinery to correctly install the viperin [4Fe-
4S] cluster; b) any additional proteins that might be necessary for its activity, and c) the 
membrane structures to which viperin is localized and which might be important for its 
activity.   
2.2.1. Viperin reduces cellular levels of FPPS.  Genes encoding full-length viperin and FPPS 
were introduced into pcDNA3.1 vectors to facilitate constitutive expression from the CMV 
promoter and equipped with N-terminal FLAG- and His-tags respectively to allow expression 
levels to be determined by immuno-staining.  Equal amounts of DNA were used to co-transfect 
HEK293T cells and the expression of both proteins followed for 48 h.  Expression levels were 
compared with cells that were singly transfected.  Co-expression of viperin and FPPS resulted in 
a significant reduction (>2-fold) of the intracellular level of FPPS relative to the FPPS only control, 
FPPS levels were significantly reduced after 48 h compared to when FPPS was expressed on its 
own [Figure 2.2(A)]. An examination of the time-course of FPPS expression revealed that under 
single and co-expression conditions, FPPS levels increased linearly from 24 to 42 h post-
transfection [Figure 2.2(B)]. However, the rate of accumulation of FPPS in the presence of viperin 
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was ~3-fold slower. In contrast, expression of viperin was independent of FPPS and reached a 
maximum at about 36 h [Figure 2.2(C)]. 
  
Figure 2.2.  Reduction of cellular FPPS levels by viperin in co-transfected HEK293T 
cells A:  Western blot analysis of viperin and FPPS expression levels as a function of time after 
transfection. GAPDH was used as the loading control.  B:  Quantification of intracellular levels of 
FPPS relative to GAPDH as a function of time in the absence and presence of co-expressed 
viperin.  C:  Quantification of intracellular levels of viperin relative to GAPDH as a function time in 
the absence and presence of co-expressed FPPS. 
 
2.2.2 Full-length viperin cleaves SAM.  We examined the ability of full-length human viperin, 
expressed in HEK293T cells, to catalyze the reductive cleavage of SAM to produce AdoH.  Tris-
buffered saline (50 mM Tris-Cl, pH 7.6, 150 mM NaCl), sonicated within an anaerobic glovebox 
(Coy Chamber), and centrifuged at 14,000 × g for 10 minutes. Extracts from cells transfected with 
either viperin and/or FPPS were prepared in Tris-buffered saline containing 1% Triton X-100 and 
incubated anaerobically at room temperature with 5 mM DTT and 5 mM dithionite for 30 min prior 
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to the addition of 200 μM SAM.  After 1 h the nucleotide pool was extracted and analyzed by LC-
MS using established protocols (14). No AdoH was detected in cell extracts lacking viperin, 
whereas AdoH was readily detected extracts prepared from viperin-expressing HEK293T cells 
[Figure 2.3].  However, the amounts of AdoH were low, 0.50 ± 0.05 nM, which is less than one 
turnover based on the concentration of viperin estimated by immuno-staining. Interestingly, co-
expression of FPPS with viperin had no effect on SAM cleavage (5’-deoxyadenosine = 0.49 ± 
0.05 nM).  These results mirrored those obtained in our in vitro studies described above, and 
suggested that either viperin may utilize SAM as a true cofactor (rather than a co-substrate) or 
that radical SAM chemistry is not involved in viperin’s regulation of FPPS.   
 
Figure 2.3.  Viperin reductively cleaves S-adenosyl-L-methionine in an uncoupled reaction.  Left 
to right un-transfected HEK293T cells; HEK293T cells transfected with FPPS; HEK293T cells 
transfected with viperin; HEK293T cells transfected with FPPS and viperin. The data represent 
the means and standard deviation of three independent biological replicates. 
 
2.2.3 Mutation of active site residues in viperin.  In a complementary approach to depleting 
the substrate for viperin, we sought to generate inactive viperin variants by mutating each of the 
conserved cysteine residues within the CxxxCxxC motif to alanine.  The C-terminal tryptophan 
residue (W361), which is thought to be an important recognition element for the cellular iron-sulfur 
cluster assembly proteins, was also mutated to alanine.  Each of these mutations abolished the 
radical SAM activity of viperin and resulted in slightly lower expression levels of viperin in the 
cells, suggesting that the mutations destabilize the enzyme slightly. (The C87A, C90A and 
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C83/87/90A mutations had lower expression compared to WT viperin by ~1.3 fold, ~2.6 fold and 
~4.5 fold, respectively; data not shown).  Most surprisingly, however, none of the mutations 
abolished the activity of viperin against FPPS [Figure 2.4].  Indeed, the C87A, C90A, and triple 
mutant variants proved to be significantly more effective at reducing the intracellular level of FPPS 
(~6-fold) compared to wild-type viperin (~2-fold). These results demonstrate that the iron-sulfur 
cluster is not required for viperin to reduce FPPS levels and imply that radical SAM chemistry is 
not involved in the regulation of FPPS by viperin. 
 
Figure 2.4.  Deletion of cysteinyl ligands to the catalytic [4Fe-4S] cluster in viperin does not 
abolish viperin’s activity against FPPS.  A. Immunoblot of FPPS, co-expressed with viperin or 
radical SAM domain mutant constructs of viperin. B. Cellular level of FPPS are normalized to 
GAPDH, and in all cases were significantly reduced when co-expressed with wildtype or mutant 
viperin enzymes; P = 0.001 - 0.0002.  
 
2.2.4 Effect of cycloleucine on viperin activity.  To examine further the mechanism by which 
viperin reduces FPPS expression we investigated the effect of suppressing intracellular levels of 
SAM by growing the cells in the presence of cycloleucine.  Cycloleucine inhibits SAM synthase 
and at high concentrations can reduce cellular SAM concentration by up to 80 % (15), thereby 
depleting the co-substrate for viperin.  Consistent with a requirement for SAM, cells transfected 
with FPPS and viperin and grown in the presence of either 20 mM or 50 mM cycloleucine did not 
exhibit the reduction in cellular FPPS levels as controls grown in the absence of cycloleucine 
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[Figure 2.5(A and B)].  However, it should be noted that expression levels of both FPPS and 
viperin relative to the GAPDH loading control were much lower, likely due to the general 
cytotoxicity of cycloleucine.   Therefore, this result should be interpreted with caution. 
  
Figure 2.5. Sensitivity of viperin activity to cycloleucine-induced reduction of intra-cellular SAM 
concentration.  A:  Western blot analysis of viperin-induced reduction of FPPS levels in the 
presence of increasing cycloleucine concentrations. GAPDH is used as loading 
control.  B:  Quantification of FPPS levels relative to GAPDH in the presence and absence of co-
transfected viperin as a function of cycloleucine concentration. (* Significantly significant 
reduction of FPPS: P = 0.0002; cycloleucine-treated cells did not show a statistically significant 
reduction in FPPS levels when viperin was co-expressed.) 
 
2.2.5 The native N-terminal amphipathic α-helix of viperin is necessary for reducing cellular 
FPPS levels. To examine whether association of viperin with the ER or lipid droplets is required 
for activity against FPPS, we employed the truncated version of viperin lacking the first 50 amino 
acids comprising of the membrane-targeting N-terminal amphipathic α-helix, but retaining the N-
terminal FLAG tag (designated as viperin-ΔN50).  Immunofluorescence imaging of HEK293T cells 
expressing viperin-ΔN50 indicated that, as expected, the truncated protein no longer localized to 
the ER (Fig. 6A). Viperin-ΔN50 expressed at similar levels to wild-type enzyme but did not 
significantly reduce the cellular levels of co-transfected FPPS (Fig 6B).  
To determine whether the activity of viperin is simply dependent on its localization to the ER, or 
whether the N-terminal plays a role in the recognition of FPPS, we replaced the N-terminal 
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amphipathic helix of viperin with the 30-residue N-terminal membrane-localizing sequence of 
hepatitis C non-structural protein 5A (NS5A) which has been demonstrated to localize NS5A to 
the ER and lipid droplets as part of the viral replication cycle (16).  The chimeric viperin was 
expressed at similar levels to wild type enzyme and the NS5A sequence effectively re-localized 
viperin to the ER [Figure. 2.6(A)].  However, the NS5A-TN50 chimeric enzyme displayed no 
activity against co-transfected FPPS [Figure. 2.6(B)]. These results suggest that the N-terminal 
amphipathic helix of viperin is important in facilitating the enzyme’s ability to decrease cellular 
FPPS levels and that localization to the ER is not of itself sufficient for this activity. 
 
Figure 2.6.  ER-localization of viperin is necessary but not sufficient for its activity against 
FPPS.  A:  Western blot analysis of viperin-induced reduction of FPPS levels in the presence of 
N-terminal mutated viperin. GAPDH is used as loading control. B:  The NS5A ER-targeting 
sequence fails to restore the activity of viperin to reduce the cellular levels of co-expressed FPPS 
(* P < 0.05). C: Top panel Viperin (red channel) co-localizes with the ER-marker protein calnexin 
(green channel).  Middle panel Deletion of the N-terminal amphipathic helix releases viperin to 
the cytosol.  Bottom panel Replacing the N-terminal amphipathic helix with the ER-targeting 
sequence of the viral protein NS5A restores viperin localization to the ER.  
 
2.2.6 Purified FPPS is unmodified by viperin.  We examined whether viperin catalyzed any 
covalent modification of FPPS that might alter its activity or lead to its degradation in the cell. His-
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tagged FPPS was co-transfected with viperin into HEK293T, and the cells were cultured for 48 h. 
The cells were lysed and FPPS-purified from the lysate using nickel-nitrilotriacetic acid affinity 
resin. Control experiments were set up where FPPS was purified from HEK293T cells that lacked 
viperin. Native PAGE analysis [Figure 2.7(A)] revealed no significant difference in the 
electrophoretic mobility of FPPS isolated from the two preparations that would have been 
indicative of a post-translational modification. The specific activities of the two enzyme 
preparations were also compared and found not to differ significantly [Figure 2.7(B)]. kcat for 
FPPS expressed on its own was 20 ± 2.3 min−1, whereas kcat for FPPS co-expressed with viperin 
was 15 ± 4.0 min−1; these values are similar to those reported previously(12). LC-ESI-MS analysis 
of FPPS from each preparation showed no difference in the mass indicative of a covalent 
modification [Figure 2.7(C and D)] The observed weight of 42,838 Da differs from the predicted 
mass of 42,926 Da by 88 Da, which corresponds to the loss of the N-terminal methionine followed 
by N-terminal acetylation (17). Lastly, no proteolytic fragments of FPPS were evident when FPPS 
was co-expressed with viperin as judged by immunoblots probed with a polyclonal antibody to 





Figure 2.7.  FPPS recovered from viperin-expressing cells is un-modified.  A, native-PAGE 
analysis of FPPS purified from HEK293T cells. Lane 1 standard proteins (native molecular 
masses in kDa indicated on the left); lane 2, FPPS expressed in the absence of viperin; lane 3, 
FPPS co-expressed with viperin. B, activity of FPPS purified from HEK293T cells in absence and 
in presence of co-expressed viperin; the small difference in rates is not considered 
significant. C and D, LC-MS of FPPS purified from HEK293T cells in the absence (C) and 
presence of co-expressed viperin (D). No significant differences in the spectra are apparent. 
 
2.3 Discussion Most studies have focused on investigating the antiviral activity of viperin in cell-
culture based experiments in which the antiviral activity of the enzyme was assayed either by 
measuring decreases in viral titer or viral RNA levels.  The consensus from these studies is that 
viperin likely exerts its activity through different pathways that depend on the particular virus and 
that it interacts with multiple cellular and viral proteins in the process (8,16,18-20).  Viperin was 
only predicted to be a member of radical SAM superfamily during this preliminary stage of study, 
and it was unclear what reaction, if any, the enzyme catalyzes to effect it’s antiviral activity.  To 
partly address this question, recombinantly produced viperin has been characterized in vitro and 
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its ability to reductively cleave SAM to form 5’-deoxyadenosine, a hallmark of radical SAM 
enzymes, has been demonstrated, both in this work and previously (13).  However, the activity 
was measured only based on the uncoupled reductive SAM cleavage of viperin, as the role of 
CTP as co-substrate of viperin was not discovered at that time. Therefore, in the light of the new 
information, there can be a new explanation to the relevance of radical SAM chemistry to viperin’s 
physiological function in targeting FPPS.  
Our studies aimed to investigate, at the biochemical level, the interaction of viperin with its best-
documented target, FPPS (6).  Our initial, unsuccessful, attempts to demonstrate any effect of 
viperin on FPPS using purified proteins in vitro, necessitated a change of approach to studying 
their interaction in cellulo.  The over-expression of both proteins in HEK293T cells, which may not 
be considered truly physiological conditions, nevertheless allows the proteins’ interaction to be 
examined under conditions in which any necessary accessory proteins and cofactors are likely to 
be present.  Moreover, it proved possible to recover FPPS from the cells and biochemically 
characterize the effect of viperin on the enzyme. 
Our experiments demonstrate that viperin depresses the cellular levels of co-expressed FPPS.  
This is consistent with earlier observations that viperin reduced the activity of endogenously 
expressed FPPS (6).  Our results suggest the reduction in activity is due to increased degradation 
of FPPS, rather than a covalent modification of the enzyme. This supported by the fact that FPPS 
purified from HEK293T cells co-transfected with viperin exhibited the same specific activity as 
FPPS expressed in the absence of viperin and furthermore contained no covalent modifications 
as assessed by ESI-MS.  We consider it very unlikely that viperin in some way regulates 
transcription, due to the fact that FPPS is expressed from an artificial plasmid; it is similarly 
unlikely that viperin regulates the translation of FPPS mRNA, as FPPS is a cytoplasmic enzyme 
whereas viperin is localized to the ER.   
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A surprising result is that viperin does not appear to depress FPPS levels by a radical SAM 
mechanism.  Our observation that mutating the conserved cysteinyl ligands to the catalytic FeS 
cluster actually potentiates, rather than abolishes, viperin’s ability to decrease FPPS levels is 
intriguing and leaves open the molecular basis for viperin’s activity.  These observations are in 
accord with previous studies in which mutating the conserved cysteinyl residues failed to abolish 
the ability of viperin to inhibit the replication of HCV (16) and DENV-2 (19) viruses.  The sensitivity 
of viperin activity to cycloleucine suggests that SAM may still be required for activity.  However, 
this result should be interpreted with caution as given the general toxicity of cycloleucine it may 
be that it decouples FPPS regulation by viperin through another, indirect mechanism.   
The N-terminal of viperin appears to be essential for viperin’s activity against of FPPS, as 
replacing this region by a different ER-localizing sequence failed to restore activity.  This suggests 
that the N-terminus plays an important role in recognizing FPPS.  We hypothesize that viperin 
might operate by recruiting additional, as yet unidentified, proteins that would be necessary for 
FPPS degradation, for example by targeting it for degradation by the proteasome.  In fact, viperin 
is shown to promote the degradation of its cellular and viral target proteins through proteasome-
mediated degradation (e.g. mitochondrial protein HADHB, viral protein NS5A and NS3) (21). 
Interestingly, viperin also has been shown to facilitate K63-linked ubiquitination of the kinase, 
IRAK1, by the E3 ubiquitin ligase, TRAF6, which are proteins that play a central role in innate 
immune signaling (22).  Viperin appears to do this by co-localizing these proteins to lipid bodies 
and thus it appears reasonable that a similar mechanism may be operating in the case of FPPS 
(although we detected no evidence for ubiquitination in our studies).  
The question now arises as to whether viperin really is a radical SAM enzyme.  We have 
demonstrated for, the first time, that the full-length enzyme expressed in human cells possesses 
the ability to reductively cleave SAM to form 5’-deoxyadenosine.  However less than one turnover 
was observed and this presumably represented uncoupled activity. Further investigation on 
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viperin’s radical SAM activity to produce 5’-deoxyadenosine with FPPS in the presence of CTP 
may results in a higher turnover number. Our results discount a radical mechanism for its 
interaction with FPPS, but it is still possible that radical SAM chemistry plays a role in regulating 
other cellular or viral proteins. For example, in contrast to viruses such as Influenza A virus that 
bud from cholesterol rich lipid rafts and are thus sensitive to FPPS inhibition, flaviviruses such as 
tick-born encephalitis virus (TBEV) are restricted by viperin but do not require lipid rafts for 
budding.  Indeed it has been shown that inhibition of FPPS by ibandronate has no effect TBEV 
replication (23).  
For TBEV, it was shown that whereas localization to the ER was essential to reduce viral titer, 
that this was not dependent on identity of the ER-localizing sequence (23).  Inhibition of 
intracellular SAM levels by cycloleucine attenuated viperin’s activity against TBEV although this 
result may be subject to the caveats noted above for our experiments.  Significantly, mutation of 
the conserved cysteine residues or the C-terminal tryptophan of viperin, which is important for 
installation of the FeS cluster by CIAO1, abolished viperin’s inhibition of TBEV replication 
indicating that an intact FeS cluster was essential for activity.  These observations all point to a 
different mode of action pertaining to viperin’s activity against TBEV and other flaviviruses such 
as DENV-2 and WNV.  The results obtained with TBEV are consistent with the involvement of 
radical SAM chemistry, although they do not demonstrate that such chemistry occurs in vivo.  
In summary, our studies demonstrate that viperin reduces FPPS activity by reducing cellular 
levels of the enzyme. This activity is dependent on the N-terminal sequence of viperin but not 
dependent on radical SAM chemistry.  It appears most likely that viperin targets proteins using 
different recognition elements, however the molecular basis of viperin’s antiviral action remains 
unclear, as does the involvement of radical SAM chemistry in it cellular functions. 
2.4 Experimental Procedures 
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Materials. S-adenosyl-L-methionine, 5’-deoxyadenosine, cycloleucine, and mouse monoclonal 
FLAG antibody (M2) were obtained from Sigma. Mouse monoclonal glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibody (6C5) was from EMD Millipore. Mouse monoclonal 6x-His tag 
antibody (HIS.H8) was purchased from Thermo Scientific. Isopentenyl pyrophosphate (IPP) and 
geranyl pyrophosphate (GPP) were purchased from Isoprenoids, LC. [4-14C]-IPP was purchased 
from Perkin Elmer. HEK293T cell line was obtained from ATCC. The pcDNA3.1(+) expression 
vector was purchased from Invitrogen. FuGENE HD transfection reagent was purchased from 
Promega. All other reagents and materials were purchased from commercial suppliers and were 
of the highest grade available. 
Cloning of viperin for bacterial expression in E. coli.  The gene encoding viperin (GenBank: 
AAL50053.1) was engineered to contain two unique Spe1 sites, allowing the removal of the N-
terminal amphipathic alpha helix if necessary. This new construct was named M1Q/W2L-viperin.  
A naturally occurring Spe1 site (5’-A▼CTAGT-3’) occurs between residues Q50 and L51.  The 
first 6 residues of the wild-type viperin sequence (MWVLTP) lend itself to addition of a Spe1 site 
by simple point mutation of M1 to Q and W2 to L.  Addition of a new start methionine yields the 
final M1Q/W2L-viperin sequence of MQLVLTP.  Since the radical SAM domain begins at residue 
Y77, this design provides a simple strategy at generating truncated viperin.  The gene for 
M1Q/W2L-viperin was codon-optimized for expression in E. coli with an N-terminal 6x histidine 
tag and purchased from GenScript sub-cloned into pET28 expression vector.  A TEV protease 
cleavage site was included for optional removal of the histidine tag post purification. This yields a 
383 amino acid protein with a predicted molecular weight of 44,630.31 Da. 
Cloning of truncated M1Q/W2L-viperin for bacterial expression in E. coli.  Truncated M1Q/W2L-
viperin, in which residues L24-Q72 were removed, was created by standard molecular biology 
techniques through Spe1 restriction digestion of the M1Q/W2L-viperin pET28 plasmid and 
confirmed by sequencing.  This yields a 334 amino acid protein with an expected molecular weight 
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of 38,932.4 Da.  Without considering the His tag and TEV site, residues L24-Q72 correspond to 
the removal of residues 3-50 of M1Q/W2L-viperin leaving 27 residues before the radical SAM 
domain. 
Cloning of FPPS for bacterial expression in E. coli.  The FPPS gene (GenBank: AAA52423.1) 
was codon-optimized for expression in E. coli with an N-terminal 6x HIS tag and purchased from 
GenScript sub-cloned into pET28 expression vector.  A TEV protease cleavage site was included 
for optional removal of the histidine tag post purification.  This yields a protein of 374 residues 
with a calculated molecular weight of 42,925.8 Da. 
Bacterial expression of M1Q/W2L-viperin and FPPS from E. coli.  To prepare 1 L main culture, a 
5 mL seed culture of sterile LB containing 50 µg/mL kanamycin was inoculated with BL21(DE3) 
E. coli cells containing the pET28 vector containing the appropriate gene.  The cells were 
incubated at 37 °C with shaking at 240 rpm overnight.  The next morning, the saturated 5 mL 
overnight was transferred to 1 L of sterile 2xYT media containing 50 µg/mL kanamycin.  The 1 L 
culture was incubated at 37 °C with shaking at 150 rpm until the OD600 reached approximately 
1.0 (5-6 h).  The culture was chilled at 4 °C for 30 min and protein expression was induced by 
adding IPTG to a final concentration of 0.1 mM.  The culture was further incubated at 18 °C with 
shaking at 150 rpm overnight (approx. 18 h).  Cells were harvested by centrifugation at 5,000 rpm 
for 30 min at 4 °C.  Cell pellet was stored at -80 °C until ready for use.  Protein expression was 
confirmed by SDS-PAGE. 
Purification of truncated M1Q/W2L-viperin from BL21(DE3) E. coli cells.  All steps were performed 
in a Coy chamber (O2 <25 ppm) or under a nitrogen atmosphere using anoxic buffers unless 
otherwise noted.  The cell pellet from a 6 L culture was resuspended in 100 mL lysis buffer (10 
mM tris-HCl, 300 mM NaCl, 5 mM imidazole, 1 mM β-mercaptoethanol, 5mM dithionite to act as 
oxygen scavenger, 1 tablet/10 mL complete mini protease inhibitor tablet - Roche, 1 mg/mL 
lysozyme, benzonase nuclease, 10% glycerol, pH 8.0) and the suspension shaken for 30 min.  
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Cell lysis completed by minimal sonication outside the Coy chamber.  The lysate was taken back 
into the Coy chamber and allowed to briefly equilibrate with the anoxic environment prior to 
removal of the cell debris by centrifugation (17,000 rpm, 30 min,  
4 °C).  The supernatant loaded onto a super-loop connected to a 5 mL HIS-Trap (GE)  
equilibrated in Buffer A (10 mM tris-HCl, 300 mM NaCl, 10 mM imidazole, 10% glycerol, pH 8.0) 
and the purification carried out by FPLC outside the Coy chamber with a flow rate of 1 mL/min 
(the column was kept at 10-15 °C by surrounding it with cold packs).  The column was washed 
with Buffer A until the absorbance at 280 nm stabilized and the protein eluted with a linear gradient 
of 0-100% Buffer B (10 mM tris-HCl, 300 mM NaCl, 500 mM imidazole, 10% glycerol, pH 8.0) 
over 60 min at 1 mL/min.  Elution fractions (15 total) were collected in 2.5 mL aliquots into vials 
followed by the addition of 500 uL of a 30 mM dithionite solution (Cf = 5 mM dithionite in 3 mL).  
Fractions containing truncated M1Q/W2L-viperin were pooled, centrifuged to remove precipitated 
protein, divided into 2mL aliquots, and stored at -80 °C until ready for reconstitution.   
Bradford analysis (which was used instead of the calculated extinction coefficient because the 
purified protein contained high levels of imidazole which would interfere with the A280 reading) 
established the enzyme stock to be 1 mg/mL (prior attempts to dialyze the pooled enzyme stock 
resulted in significant protein precipitation).  Protein yield was ~ 4 mg/L culture. 
Reconstitution of Truncated M1Q/W2L-Viperin Purified from E. Coli.  Reconstitution was 
performed with slight modification of the protocol described by Duschene and Broderick (13). All 
steps were performed in a Coy chamber (O2 <25 ppm) using anoxic buffers unless otherwise 
noted.  The following protocol is for ~ 2 mg of purified truncated M1Q/W2L-viperin.  The day prior 
to reconstitution, an 8.3 mL PD-10 desalting column was equilibrated with copious amounts (~50 
column volumes) of reconstitution buffer (10 mM tris-HCl, 300 mM NaCl, 10% glycerol, pH 8.0) in 
order to make the column as oxygen free as possible.  The column was left to equilibrate 
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overnight. The truncated M1Q/W2L-viperin stock solution was slowly thawed on a cold pack and 
the u.v.-visible spectrum recorded using an anaerobic cuvette as a prereconstitution control.  The 
protein was incubated with DTT (Cf = 5mM) for 20 min on the cold pack with gentle magnetic 
stirring.  FeCl3 (Cf = 150 uM, 6 equivalents) was added drop-wise to the stirring solution and 
incubate an additional 20 min.  Na2S  
(Cf = 150 uM, 6 equivalents) was added in one aliquot and stirred for 2 h on the cold pack.  The 
cold pack was removed and stirred for an additional hour.  EDTA (Cf = 2 mM) was added in one 
aliquot and stirred for 30 min to chelate any free iron and sulfide remaining in solution and solution 
diluted to 2.5 mL with reconstitution buffer (it is important not to exceed 2.5 mL as it is the limit for 
a PD-10 column).  Load the reconstitution solution onto the PD-column and elute the protein.  
Elution aliquots were collected in 2 mL fractions.  The first two fractions (dark reddish brown) were 
pooled and the u.v.-visible spectrum recorded using an anaerobic cuvette.  The reconstituted 
protein was divided into 500 µL aliquots and stored at -80 °C.  Since the desalting column 
exchanges the truncated M1Q/W2L-viperin into reconstitution buffer, the concentration can now 
be determined using a calculated extinction (averaging the fully reduced and fully oxidized states) 
of ε280 = 42,712.5 M-1cm-1.  Reconstituted protein yielded was typically ~ 26 µM (1 mg/mL). 
Purification of FPPS from BL21(DE3) E. coli cells.  FPPS was purified as described for truncated 
M1Q/W2L-viperin without the use of anoxic buffers, DTT, or Coy chamber.  Elution fractions 
containing FPPS were pooled, concentrated and dialyzed 4x into 1 L of 10 mM tris-HCl, pH 8, 
10% glycerol at 4 °C.  Using a calculated extinction coefficient (average between the enzyme’s 
oxidized and reduced states) of ε280 = 56,458 M-1cm-1, the final concentration was adjusted to 
15 mg/mL, aliquoted and stored at -80 °C.  FPPS (Mr 42,925.8 Da) was determined to be to > 
95% as judged by SDS-PAGE.  Protein yield was ~ 50 mg/L culture. 
In vitro SAM cleavage assay of Viperin in the presence of FPPS.  The SAM cleavage assay was 
performed with slight modification of the protocol described by Duschene and Broderick (13). 
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Reagents were used in final concentrations of 78 µM reconstituted truncated M1Q/W2L-viperin, 
5 mM DTT, 5 mM dithionite, 200 µM SAM, 10 mM tris-HCl at pH 8.0, 300 mM NaCl, and 10% 
glycerol in a total volume of 515 µL.  The assay mixture was allowed to incubate at room 
temperature for 30 min prior to starting the reaction by the addition of SAM.  The assay was 
allowed to age for 60 min at room temperature.  The assay was quenched by heating at 95 °C for 
10 min.  The solution was chilled to 4 °C and precipitated proteins removed by centrifugation.  The 
supernatant was decanted into a Microcon Ultracel YM30 spin column, and centrifuged at 13,000 
rpm, 4 °C for 1 h to ensure all the solution passes through.  The production of 5’-deoxyadenosine 
was then analyzed by reverse phase HPLC. 4.2.6.2. Detection of 5’-deoxyadenosine by HPLC.  
5’-deoxyadenosine was analyzed by HPLC on a Vydac 201SP54 250 x 4.6 mm C18 reverse-
phase column with a 5 µm particle size.  100 µL were injected onto the column (pre-equilibrated 
in Solvent A) using a 100 µL injection loop.  5’-deoxyadenosine was eluted using a gradient of 0 
- 5 min, 0 - 15% B; 5 - 10 min, 15 - 75% B; 10 - 11 min, hold 75% B, 11 - 15 min, hold 100% B, 
15 - 20 min, hold 0% B at a flow rate of 1 mL/min.   
5’-deoxyadenosine was detected by monitoring its absorbance at 260 nm (RT = 7.50 min) and 
confirmed by ESI-MS in the positive ion mode ([M+H]+ = 252.1).  The amount of 5’-
deoxyadenosine produced was determined by peak integration and compared to a standard 
curve.  L-tryptohan (40 ng/µL, RT = 9.95 min) was used as an internal standard.  (Solvent A = 
0.1% TFA in water, Solvent B = 0.1% TFA in acetonitrile). 
Radioactive FPPS assay in the presence of purified viperin.  Enzymatic activity was monitored 
through modification of a radioactivity-based assay described Kavanagh and coworkers (24). 
Reagents were used in final concentrations of 4.7 nM FPPS (0.4ng/µL), 20 µM GPP, 18 µM IPP, 
0.2 µCi/mL [4-C14]-IPP (specific activity 10.8 Ci/mol), 5 µg/mL BSA, 2 mM DTT, 2 mM MaCl2, 
10% glycerol, 50 mM tris-HCl at pH 8.0 in a final volume of 800 µL.  All reagents except enzyme 
were combined into a 1.5 mL eppendorf tube and equilibrated to 37 °C over 5 min.  The assay, 
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initiated by the addition of enzyme, was allowed to age and over the course of 15 min, 100 µL 
aliquots were quenched by addition into 200 µL of a 4:1 MeOH/HCl solution pre-equilibrated at 
37 °C.  The quenched solution was further incubated for 10 min at 37 °C, allowing for the selective 
hydrolysis of FPP to farnesol and nerolidol.  The hydrolyzed FPP products were extracted into 
400 µL ligroin and vortexed for 2 min.  200 µL of the ligroin layer was diluted into 4 mL scintillation 
cocktail and the absolute C14 content in decays per minute (DPM) of the extracted FPP hydrolysis 
products was then determined using the LS6500 Beckman liquid scintillation counter’s factory 
installed quench curve. 
Cloning of human viperin and FPPS. The genes encoding human viperin (GenBank: AAL50053.1) 
and farnesyl pyrophoshphate synthase (FPPS; GenBank: AAA52423.1) were purchased from 
GenScript. Both genes were subsequently amplified via polymerase chain reaction (PCR) and 
subcloned into the pcDNA3.1(+) vector (Invitrogen). The primers for the pcDNA3.1(+)-viperin 
construct introduced an N-terminal 3X-FLAG tag –(DYKDHDGDYKDHDIDYKDDDDK) and the 
Kozak consensus sequence (5'-GCCAAC-3') for downstream protein expression in eukaryotic 
cells.(25) Similarly, the primers for the pcDNA3.1(+)-FPPS construct introduced an N-terminal 
hexahistidine tag and the necessary Kozak sequence. Two additional N-terminal 3X-FLAG tagged 
variants of human viperin were also constructed using standard Gibson assembly cloning 
methods. The first variant, viperin-ΔN50, featured a deletion of the first 50 amino acids of the N-
terminus. The second variant, NS5A-TN50, included a replacement of the native N-terminus by 
the first 30 amino acid residues from the hepatitis C virus non-structural 5A (NS5A) protein. The 
gene encoding the NS5A protein was obtained from AddGene as the pCMV-Tag1-NS5A plasmid. 
The point mutations described in this paper were introduced using the QuikChange site-directed 
mutagenesis method (Agilent Technologies, Mississauga, ON). DNA sequencing confirmed the 
presence of each gene and the absence of any PCR-induced errors for each construct.  
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Expression of human viperin and FPPS in HEK293T cells. Over-expression of the full-length 
recombinant human viperin and FPPS proteins was accomplished through transient transfection 
of HEK293T cells (cultivated in DMEM supplemented with 10% FBS and 1% antibiotics) with the 
pcDNA3.1(+)-viperin construct or the pcDNA3.1(+)-FPPS construct, respectively. In addition, co-
transfection of both DNA constructs allowed for co-expression of viperin and FPPS within the 
HEK293T cells. The same transfection protocols were used for expression of each of the viperin 
variants. Briefly, 2.5 µg of the respective plasmid DNA construct was mixed with FuGENE HD 
reagent in a 3:1 ratio, incubated at room temperature for 15 min, and then added to HEK293T 
cells at 40% confluence on a 35-mm dish. The transfected cells were then grown for up to 48 h, 
gently pelleted, and stored at –80 °C until use. Expression of viperin and FPPS proteins was also 
examined following growth of HEK293T cells in the presence of cycloleucine, an inhibitor of S-
adenosyl-L-methionine synthesis. Transfected HEK293T cells were grown for 48 h in the 
presence or absence of 20 mM or 50 mM cycloleucine. In all cases, protein expression was 
confirmed through western blotting with the appropriate anti-FLAG (Sigma-Aldrich) and/or anti-
His (Thermo Scientific) monoclonal antibodies using GAPDH as a loading control. 
Chemiluminescent images were acquired on a Bio-Rad ChemiDoc Touch Imager. Where noted, 
rabbit anti-FPPS polyclonal antibodies (Proteintech) were also used to check for FPPS 
expression. 
Immuno-blotting Cell lysates were subjected to electrophoresis and proteins transferred to PVDF 
membranes by standard methods.  
Immunofluorescence and immuno-blotting. HEK293T cells were grown to 30% confluence on 
poly-L-lysine- coated coverslips and then transiently transfected with wild-type viperin, TN50, or 
NS5A-TN50 plasmid DNA. After 48 h the cells were fixed with 3% paraformaldehyde, 
permeabilized with 0.5% Triton X-100 diluted in PBS buffer, and stained with mouse monoclonal 
anti-viperin (Abcam) and rabbit polyclonal anti-calnexin (Abcam) antibodies. Protein localization 
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was visualized with Alexa Fluor 647-conjugated goat anti-mouse (Life Technologies) and Alexa 
Fluor 488-conjugated goat anti-rabbit (Abcam) antisera. Images were acquired on an Olympus 
IX-81 confocal microscope.  Immuno-blotting and imaging of proteins was performed by standard 
methods using chemiluminescence to visualize proteins.  Blots were visualized and band 
intensities quantified using a BioRad ChemiDoc Touch imaging system.  Quantitative 
measurements of protein expression levels reported here represent the average of at least 3 
independent biological replicates.  
Cleavage of SAM by viperin in vivo. HEK293T cells over-expressing viperin were harvested from 
a 10 cm2 dish, resuspended in 200 µL of anoxic Tris-buffered saline (50 mM Tris-Cl, pH 7.6, 150 
mM NaCl) containing 1% Triton X-100, sonicated within an anaerobic glovebox (Coy Chamber), 
and centrifuged at 14,000 × g for 10 minutes. DTT (final concentration 5 mM) and dithionite (final 
concentration 5 mM) were added to the cell lysate. The assay mixture was incubated at room 
temperature for 30 min prior to starting the reaction by the addition of SAM (final concentration 
200 μM).  The assay was incubated for 60 min at room temperature after which the reaction 
stopped by heating at 95 °C for 10 min.  The solution was chilled to 4 °C and precipitated proteins 
removed by centrifugation. The supernatant was then extracted with acetonitrile. Aliquots of 20 
µL were subsequently derivatized with benzoyl chloride as described previously (14). The 
samples were analyzed in triplicate for the presence of 5’-deoxyadenosine by HPLC-tandem 
mass spectrometry, using an Acquity HSS T3 C18 chromatography column (1 mm x 100 mm, 1.8 
um, 100 Å pore size) on a Waters nanoAcquity ultra performance liquid chromatograph interfaced 
to an Agilent 6410 triple quadrupole mass spectrometer.  Mobile phase A was 100 mM ammonium 
acetate with 0.15% formic acid.  Mobile phase B was acetonitrile.  The flow rate was 100 µL/min, 
and the gradient was as follows:  initial, 0% B; 0.01 min, 17% B; 0.5 min, 40% B; 2.99 min, 60% 
B; 3.00 min, 100% B; 3.99 min, 100% B; 4.00 min, 0% B; 5.00 min, 0% B.  Internal standards 
included benzoylated adenosine, r.t. 3.33 min, 3'-deoxyadenosine, r.t. 3.85 min and 5’-
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deoxyadenosine, r.t. 4.05 min. Peaks were integrated using Agilent MassHunter Workstation 
Quantitative Analysis for triple quadrupole, version B.05.00. 
Purification of FPPS from HEK 293T cells. All purification steps were carried out at 4 °C.  Cells 
overexpressing FPPS or FPPS and viperin (0.5 g, wet weight) were resuspended in 2 mL of Tris-
buffered saline, 0.1% Tween-20, and 20 mM imidazole (pH 7.5) containing a mix of protease 
inhibitors (Sigma-Aldrich). The mixture was briefly sonicated followed by centrifugation at 14,000 
rpm for 10 min. The supernatant was then mixed with 100 µL of Ni-NTA resin, pre-equilibrated 
with Tris-buffered saline and 20 mM imidazole (pH 7.5). Following a 1 h incubation period, the 
mix was washed twice with 1 mL Tris-buffered saline and 20 mM imidazole (pH 7.5) and then 
twice more with 1 mL Tris-buffered saline, 20 mM imidazole, and 10% glycerol. FPPS was eluted 
with 200 µL Tris-buffered saline, 250 mM imidazole, and 10% glycerol. The protein was 
concentrated and buffer-exchanged into 10 mM Tris-Cl (pH 8.0) containing 10% glycerol and 
frozen at –80 °C until use. The purity of the isolated FPPS protein was assessed by SDS PAGE 
(10 % gel). The Lowry assay method was used to determine the concentration of the protein.  
Radiolabeled assays for FPPS activity. The catalytic activity of FPPS was monitored through the 
use of a previously described radiolabeled assay (24), with slight modification. Each 800 µL 
reaction mixture contained 50 mM Tris-Cl (pH 8.0), 10% glycerol, 2 mM MgCl2, 2 mM DTT, 18 µM 
IPP, 10.8 Ci/mol [4-14C-IPP], 20 µM GPP, and 4.7 nM FPPS. The reactions were initiated by the 
addition of FPPS and incubated at 37 ºC. Every 4 minutes a 100 µL aliquot was removed and 
quenched with 200 µL of a 4:1 MeOH/HCl solution, vortexed briefly, and incubated at 37 ºC for 
10 minutes. Each quenched sample was subsequently extracted with 400 µL Ligroin and vortexed 
for 30 seconds. A 200 µL aliquot of the Ligroin layer was diluted in 4 mL of scintillation cocktail 
followed by scintillation counting on a Beckman LS 6500 Scintillation Counter. The experiment 




LC-MS Analysis of FPPS. Purified protein samples that were buffer exchanged into 10 mM Tris-
Cl (pH 8.0) containing 10% glycerol were analyzed using an Agilent 6250 Accurate-Mass Q-TOF 
LC/MS system. Samples (3 µL) were injected into a Zorbax Eclipse Plus C18 column equilibrated 
with 4.75% acetonitrile and 0.1% formic acid. Proteins were eluted over a 6-minute gradient from 
4.75% to 95% acetonitrile at a constant flow rate of 0.4 ml/min. Protein masses were obtained 
using ESI in positive ion mode and analyzed using Agilent MassHunter Quantitative Analysis 
software. 
Pull-down assay of wild-type viperin and FPPS expressed in HEK293T cells.  All steps were 
performed on ice or at 4 °C.  Typically, HEK293T cells cotransfected with wild-type viperin and 
FPPS were resuspended in 500 µL lysis buffer containing tris-buffered saline, 1% Triton X-100, 
and 20 mM imidazole, pH 7.4 and lysed sonication.  25 µL Ni-NTA equilibrated in lysis buffer was 
added and the solution incubated for 10 - 15 min at room temperature with shaking to allow the 
HIS-tagged FPPS to bind to the resin.  The solution was centrifuged to pellet the resin and the 
supernatant (flow-through) removed carefully by pipette.  The resin was washed 3x with 500 µL 
lysis buffer (60x resin volume).  Bound protein was eluted by incubating the resin with 50 µL lysis 
buffer (2x resin volume) containing 500 mM imidazole for 5 min.  The resin was separated by 
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The Interaction of Viperin with Hepatitis C Virus Non-Structural 
Protein 5A Inhibits the Catalytic Activity of Viperin 
 
(Works in this chapter are part of the manuscript submitted to Biochemistry) 
 
 
3.1 Introduction In addition to regulation of cellular metabolic pathways, viperin appears 
to exert antiviral activity against a wide range of viruses by interacting with various viral 
proteins. Especially, it has been shown to inhibit several flaviviridae family viruses; 
including Hepatitis C Virus (HCV) (1-3), dengue virus (DENV) (4,5), tick-borne 
encephalitis virus (TBEV) (6-8), West Nile virus (WNV) (4), and Zika virus (ZIKV) (8-11).  
Viral non-structural proteins, encoded by flaviviridae family viruses, are the primary innate 
immunity pathway antagonists in flavivirus/hepacivirus infection (12).  These proteins are 
processed from viral polyprotein precursor through posttranslational modification and are 
essential for viral replication and assembly and modulating innate immunity of host cells 
(12,13).  
The molecular basis of viperin’s inhibitory effects against the viral proteins seems to be 
virus-specific. For HCV and DENV, it was shown to inhibit viral replication by interacting 
with the non-structural proteins (1,5,11,14), while for TBEV, it impedes the synthesis of 
positive-strand viral RNA (7). A recent study revealed that viperin can also inhibit ZIKV
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 and TBEV replication by interacting with both structural and non-structural viral proteins 
(8). The regulation of viral proteins by viperin unveils the mechanistic insights of its 
antiviral activity. However, the underlying unifying mechanism by which viperin targets a 
broad range of viruses is still under investigation.  
Viperin was shown to catalyse the formation of a novel antiviral ribonucleotide by 
dehydration of CTP to 3’-deoxy-3’, 4’-didehydro-CTP (ddhCTP) that acts as a chain 
terminator for the RNA-dependent RNA polymerases (RdRp) in flaviviruses. This may 
explain one facet of viperin's antiviral activity against flaviviruses (15). However, it is not 
yet clear whether and how viperin’s ability to produce ddhCTP is regulated in the presence 
of viral structural and non-structural proteins.  
In this study, we focus on viperin’s interaction with the Non-structural protein 5 (NS5A) 
from the Hepatitis C virus and how this interaction leads to the modulation in ddhCTP 
production by viperin. NS5A is one of the major viral core proteins, playing an important 
role in HCV replication as an essential component of the viral replication complex (1,3).  
NS5A localizes at the cytoplasmic face of the endoplasmic reticulum and lipid droplets 
together with the RdRp, NS5B.  Interaction of NS5A with the sterol regulatory host protein, 
vesicle-associated membrane protein-associated protein A (VAP-33), is also needed to 
support HCV replication (14,16). Through FRET analysis (3), confocal microscopy and 
co-immunoprecipitation studies (1), viperin was shown to interact with NS5A through 
VAP-33 at lipid droplets.  This observation suggests that the interaction between viperin 
and VAP-33 may interfere with the association of NS5A and VAP-33, thereby perturbing 
the viral replication complex formation [Figure 3.1].  Mutagenic analysis showed that the 
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C-terminal domain of viperin is required for its interaction with NS5A through VAP-33 in 
HEK293T cells.   
Here, collaboratively with Ayesha Patel and Timothy Grunkemeyer, we have investigated 
the interactions between viperin, NS5A and VAP-33 and their effect of virperin’s catalytic 
activity to produce 5’-deoxyadenosine using proteins transiently expressed in HEK293T 
cells and with pure proteins in vitro.  We show that full-length viperin interacts with NS5A 
in presence of host cell factor VAP-33 and leads to its degradation through the 
proteasomal degradation pathway.  Concomitantly, NS5A and VAP-33 reduce the 
ddhCTP-forming activity of viperin.  The formation of the complex between viperin, NS5A 
and VAP-33 is dependent on the membrane localization of all three proteins. The present 
study provides insight into the mechanism of regulation of a viral protein by viperin, 
coupled with its enzymatic activity.  
 
Figure 3.1: Overview of viperin’s function in inhibiting Hepatitis C virus replication. 
Role of viperin in restricting HCV replication complex formation by interacting with the 























3.2.1 Viperin interacts with NS5A at endoplasmic reticulum We first examined the 
interaction of viperin with NS5A and the c-terminal cytoplasmic domain of VAP-33 (VAP-
33C; human homolog with amino acid residues 156-242), which previous studies (1) had 
shown is responsible for binding to NS5A. We conducted immunoprecipitation 
experiments using viperin or viperinΔ3C (viperin variant with iron-sulfur cluster-chelating 
cysteine residues mutated to alanine) as bait proteins and NS5A and/or VAP-33C as prey 
proteins.   
NS5A was found to co-precipitate with viperin [Figure 3.2(a)], independent of the 
presence of VAP-33C. NS5A was also co-precipitated by the viperinΔ3C mutant [Figure 
3.2(a)], suggesting that the presence of the iron-sulfur cluster is not an essential part of 
the viperin-NS5A interaction. Both viperin and viperinΔ3C mutant were found to 
precipitate VAP-33C individually. We further confirmed the co-localization of viperin, 
NS5A and VAP-33C by immuno-fluorescence microscopy of fixed HEK293T cells, where 
NS5A was observed to co-localize with viperin at endoplasmic reticulum in the presence 
and absence of VAP-33C [Figure 3.2(c)]. 
We also assessed the importance of the N-terminal amphipathic helix of viperin for its 
interaction with NS5A and VAP-33C by co-immunoprecipitation using an N-terminal 
truncated viperin construct (viperin-ΔN50) that lacks the ER localizing amphipathic helix 
as the bait protein. In this case NS5A and VAP-33C showed a weaker interaction with 
viperin-ΔN50 [Figure 3.2(b)], indicating that the localization of viperin to the endoplasmic-





Figure 3.2. Viperin interacts with NS5A and co-localizes at endoplasmic-
reticulum.  (a) HEK293T cells transfected viperin or viperin-Δ3C (lacking the iron-sulfur 
cluster), NS5A and or FLAG-VAP-33C (c-terminal of VAP-33) were immunoprecipitated 
using anti-viperin antibody and blots probed with anti-NS5A monoclonal and anti-FLAG 
(for VAP-33C) antibody.  The results demonstrate that viperin and viperin-Δ3C pull down 
both NS5A and VAP-33C and the iron-sulfur cluster is not required for viperin to bind 
NS5A and VAP-33C. (b) Co-immunoprecipitation using viperin or viperin-ΔN50 (lacking 
the N-terminal amphipathic helix) as bait and NS5A and VAP-33C as prey protein.  The 
results demonstrate that the N-terminal amphipathic helix is important for viperin to bind 
NS5A and VAP-33C.  (c) Immunofluorescence microscopy of HEK293T cells co-
transfected with viperin (upper panel) or viperin-Δ3C (lower panel) and NS5A, in presence 
of VAP-33C. The cells were immobilized 30 hours post-transfection and stained for viperin 
(green) and NS5A (red).  Both viperin and viperin-Δ3C co-localize (yellow in merged 





3.2.2. Viperin leads to the degradation of NS5A through proteasomal degradation 
pathway Viperin has been found to alter the cellular expression levels of various proteins 
it interacts with (8,17). Therefore, we next examined how co-expression of viperin altered 
the cellular levels of NS5A and VAP-33C.  Proteins were co-transfected into HEK293T 
cells and after 30 h the cells were harvested and protein expression analysed by 
immunoblotting. Co-expression with VAP-33C had no significant effect on NS5A 
expression, whereas co-expression with viperin resulted in a small decrease in NS5A 
levels.  Co-expression of both VAP-33C and viperin led to the most significant decrease 
in intra-cellular expression level of NS5A, by ~2-fold, compared to NS5A expressed on 
its own [Figure 3.3(a)]. No reduction of NS5A levels were observed in control 
experiments when empty vector (pcDNA3.1) was co-transfected with it. Similar reductions 
in NS5A levels were observed when NS5A was co-expressed with viperinΔ3C and VAP-
33C, suggesting the iron-sulfur centre is not required for this effect.   
To investigate the reason for the viperin-mediated reduction in NS5A expression, we 
examined the ability of the proteasomal inhibitor MG-132 to restore NS5A expression 
levels.  The expression levels of NS5A co-expressed with viperin or viperinΔ3C were 
restored to levels comparable to those of the controls by treatment with MG-132 [Figure 
3.3(b)].  These results suggest that viperin promotes the degradation of NS5A through 





Figure 3.3: Viperin promotes degradation of NS5A through the proteasomal 
degradation pathway. (a) HEK293T cells were transfected with NS5A, FLAG-VAP-33C 
and either viperin or viperin-Δ3C. 30 hours post-transfection NS5A levels were visualized 
by immunoblotting.  Co-expression of viperin or viperin-Δ3C and VAP-33C significantly 
decreases NS5A levels (left panel *** p = 0.0005, n = 4; right panel ****p = 0.0001, n = 
4).  (b) HEK293T cells were transfected with NS5A, VAP-33C and either viperin or viperin-
Δ3C.  6 hours post transfection cells were treated with either 50 μM MG-132 (proteasome 
inhibitor) or DMSO control; 30 hours post-transfection NS5A levels were visualized by 
immunoblotting.  MG-132 reverses the decrease in NS5A levels induced by co-




3.2.3.NS5A and VAP-33C together repress the reductive SAM cleavage activity of 
viperin to produce 5’-deoxyadenosine NS5A is known to antagonize the innate 
immune system by inactivating various ISGs (18). For example, NS5A was shown to 
disrupt dimerization and repress the enzymatic activity of Protein kinase R, a critical ISG 
in cellular antiviral response (19).  Therefore, we investigated whether NS5A might alter 
the catalytic activity of viperin.  To examine this possibility, we measured specific activity 
of viperin in HEK293T cell lysates when co-expressed with NS5A and/or VAP-33C. 
HEK293T cell-lysates were prepared under anaerobic conditions and viperin activity was 
quantified as described previously (20).  
When expressed on its own, viperin showed a specific activity to produce 5’-
deoxyadenosine, expressed as a turnover number, kobs = 7.6 ± 0.6 h-1.  When co-
expressed with VAP-33C, this activity increased slightly with kobs = 13.1 ± 1.1 h-1, whereas 
co-expression with NS5A did not change the specific activity of viperin, kobs = 8.4 ± 0.7 h-
1.  However, when viperin was co-expressed with both VAP-33C and NS5A, the specific 
activity of viperin was significantly lowered to kobs = 4.0 ± 0.4 h-1. [Figure 3.4(A), 
Appendix A.2].  VAP-33 is a known interaction partner of viperin, therefore, it was not 
unexpected to see the increase in activity of viperin (about ~1.7- fold relative to single-
expressed viperin) in its presence. However, a ~3.3-fold reduction in relative activity of 
viperin upon addition of NS5A (comparing viperin with VAP-33C alone and with both 
proteins) is quite remarkable; as this deactivation of radical SAM activity of viperin has 
not been previously observed.  
Since the deletion of membrane –localizing domain of viperin abrogated its interaction 
with NS5A and VAP-33C, we conducted the radical SAM assay on HEK293T cell lysate 
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expressing viperin-ΔN50. As expected, viperin-ΔN50 did not show any change in its 
specific activity by its own (kobs = 0.7 ± 0.04 h-1), or when co-expressed with NS5A (kobs 
= 0.5 ± 0.08 h-1) and VAP-33C (kobs = 0.7 ± 0.05 h-1) or both (kobs = 0.5 ± 0.06 h-1) [Figure 
3.4(b), Appendix A.2]. However, viperin-ΔN50 showed a relatively slower turnover 
number than full length viperin, suggesting that disruption of the membrane associated 
structure of viperin actually have an impact on its catalytic efficiency.  
 
Figure 3.4: Co-expression of NS5A and VAP-33C inhibits reductive SAM cleavage 
activity of Viperin in HEK293T cell-lysates. (a) Activity of viperin in HEK293T cell-
lysates co-expressing either NS5A and/or VAP-33C.  The amount of 5’-dA produced was 
determined after 1 hour and normalized to the amount of viperin expressed in the cell 
extract; data presented as mean ± SEM n = 3. A significant (**p=0.0033) reduction in 
reductive SAM cleavage activity was observed when viperin was co-expressed with NS5A 
and VAP-33C. (b) Activity of viperin-ΔN50 in HEK293T cell-lysates co-expressing either 
NS5A and/or VAP-33C. The amount of 5’-dA produced was determined following the 




3.2.4 The membrane-localizing domains of viperin, NS5A and VAP-33 are required 
for complex formation To examine the changes in enzymatic activity in more detail we 
attempted to reconstitute the interactions between viperin, NS5A and VAP-33C using 
purified proteins obtained by over-expression in E. coli.  However, this necessitated 
removing the membrane-binding domains of these proteins so that they could be 
produced in soluble form.  A C-terminal His6-tagged viperin lacking the first 50 membrane-
associated amino acids (viperin-ΔN50), was purified under anaerobic conditions and the 
iron-sulfur cluster was reconstituted using procedures as described previously (21).  
NS5A lacking the first 39 amino acids comprising the membrane-binding amphipathic 
helix (NS5A-ΔN39), was expressed and purified as a fusion protein with maltose-binding 
protein (MBP), followed by TEV cleavage and size exclusion chromatography as 
described in the methods section. The N-terminal His6-tagged VAP-33 construct lacking 
the last 20 amino acids of the trans-membrane domain on the C-terminus (VAP-33-
ΔC20), was purchased commercially.  
However, when the interactions between these three proteins we examined by 
immunoprecipitation using an anti-viperin antibody, no protein complexes could be 
detected [Figure 3.5(A)].  Further experiments designed to detect the formation of protein 
complexes using the lysine-reactive covalent cross-linking reagent, 
bis(sulfosuccinimidyl)suberate (BS3), similarly failed to detect any inter-protein 
crosslinking [Figure 3.5(B)].  Consistent with this, and as observed in mammalian cell 
lysate radical SAM assay, the catalytic activity of viperin-ΔN50 was unaffected by the 
presence of NS5A-Δ39, or VAP-33-ΔC20.  Under the conditions of the assay, kobs for 
viperin-ΔN50 to produce 5’-deoxyadenosine was 4.1 ± 0.3 h-1, with the lower activity 
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observed for the truncated construct being consistent with previous observations (20).  
When mixed with stoichiometric amounts of NS5A-ΔN39 or VAP-33-ΔC20, we measured 
rates of 2.7 ± 0.2 h-1 and 2.8 ± 0.1 h-1 respectively.  Finally, combining all three proteins 
yielded a comparable result with kobs = 2.8 ± 0.1 h-1 [Figure 3.6]. These results suggest 
that removing the membrane-associated domains from these proteins effectively 
abolishes the ability of the proteins to form a complex.   
 
Figure 3.5: Loss of interaction among recombinant NS5A-Δ39 and VAP-33-ΔC20 
and viperin-ΔN50 (lacking the membrane associated sequence) in vitro: (A) 
Recombinant viperin was incubated with its possible prey protein recombinant NS5A-
ΔN39 and VAP-33-ΔC20, followed by its immunoprecipitation, using anti-viperin antibody. 
The immunoprecipitated samples were immunoblotted with anti-his antibody to probe for 
the proteins. No specific interaction was observed between viperin and NS5A in presence 
and absence of VAP-33, suggesting that the membrane associated sequence of these 
interacting proteins are important for protein-complex formation. (B) Purified proteins 
were incubated with each other or by itself prior to the addition of chemical crosslinker 
BS3. The three proteins individually formed dimers and showed non-specific 
oligomerization in the presence other partner protein. The protein complex among these 







Figure 3.6: Recombinant NS5A and VAP-33, lacking the membrane associated 
domain, did not change the reductive SAM cleavage activity of recombinant viperin 
in vitro. Activity of purified viperin (viperin-ΔN50) was assessed by monitoring the rate of 
5’-deoxyadenosine production. The turnover of 5’-deoxyadenosine by viperin was 
calculated from the linear fitting curve. Viperin showed the turnover of 4.1 ± 0.3 h-1 alone 
and 2.7 ± 0.2 h-1, 2.8 ± 0.1 h-1, 2.8 ± 0.1 h-1 when incubated with recombinant NS5A 
(NS5A-ΔN39), VAP-33 (VAP-33-ΔC20) or both, respectively. Overall, no significant 




3.3 Discussion To date, most of the studies conducted on the antiviral activity of viperin 
against flaviviridae viruses have been focused on identifying physical interactions 
between viperin and viral core and non-structural proteins and correlating perturbations 
of these interactions with changes in viral replication or infectivity.  Though the importance 
of domain-specific interactions between viperin and its target viral proteins has been 
shown through mutational analysis, no investigation of the effects of these interactions on 
the recently-revealed catalytic activity of viperin have been undertaken.  The discovery 
that viperin catalyzes the formation of the antiviral nucleotide ddhCTP from CTP raises 
the question of whether the activity of viperin is modulated by the numerous proteins it 
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has been shown to interact with. Understanding the mechanism by which the synthesis 
of ddhCTP is viperin regulated by other proteins may open the way to the design of new 
antiviral therapeutics. 
Non-structural protein NS5A from HCV is one of the viral proteins that interacts with 
viperin.  NS5A interacts with the viral RNA-dependent RNA polymerase, NS5B, within the 
replication complex and is essential for genome replication (22,23).  The reported 
interaction of NS5A and viperin could either be a mechanism by which viperin inhibits 
viral replication, or an adaptation of the virus to inhibit viperin.  To investigate these 
possibilities we have examined the enzymatic activity of viperin in complex with NS5A 
and the cellular protein VAP-33, which is co-opted as part of the viral replication complex.  
By reconstituting the complex between viperin, NS5A and VAP-33 in HEK293T cells, we 
were able to investigate how NS5A and VAP-33 alter viperin’s catalytic activity.  The most 
significant difference in viperin activity was apparent when comparing the complex of 
viperin and VAP-33 and the complex of viperin, VAP-33 and NS5A, with the addition of 
NS5A reducing the activity of viperin to produce 5’-deoxyadenosine by ~ 3 fold.  This 
suggests that NS5A may have evolved, in part, to counteract the synthesis ddhCTP, 
thereby potentiating the infectivity HCV.  The localization of these proteins to the ER 
membrane or lipid droplets appears to be crucial for the complex to form.  This was 
evident from our in vivo radical SAM assay and in vitro studies using purified proteins, 
which necessitated the removal of the membrane associated domains from the proteins 
to facilitate their expression and purification.  The N-terminal truncated viperin in 
HEK293T cells and the truncated proteins failed to associate with each other as evident 
from in vitro co-immunoprecipitation and chemical crosslinking experiments.  This 
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observation is in agreement with previous studies on swine fever virus in which the N-
terminal domain of viperin was shown to be crucial to co-localize with the replication 
complex at lipid droplets in HCV and interact with NS5A (24).  
Although NS5A appears to inhibit viperin, our studies find support for the hypothesis that 
viperin exerts an antiviral effect by promoting the degradation of NS5A through the 
proteasomal degradation pathway.  This presumably occurs by ubiquitination of NS5A.  
In this respect we note that viperin has been shown to activate the E3 ubiquitin ligase 
TRAF6 in the context of innate immune signalling.  It seems plausible that viperin could 
act to recruit other E3 ligases that function in the endoplasmic reticulum-associated 
protein degradation (ERAD) pathway.  Notably, this function of viperin does not appear 
to require the iron-sulfur cluster, as the viperinΔ3C variant was equally effective in 
reducing the cellular levels of NS5A.  These findings are in accord with other studies 
showing that viperin promotes the degradation of non-structural protein NS3 in other 
flaviviruses through the proteasomal degradation pathway (8).   
In conclusion, we find opposing effects on viral replication for the interaction between 
viperin and HCV NS5A [Figure 3.7]. On one hand, NS5A appears to inhibit the activity of 
viperin to roduce 5’-deoxyadenosine, thereby reducing the potential for ddhCTP to 
interfere with replication of the viral genome.  On the other hand, viperin appears to 
decrease the expression of NS5A to limit the formation of the replication complex.  These 
studies point to complex interplay between viral proteins and cellular proteins they co-opt 




Figure 3.7: Overview of the functional interactions between NS5A and viperin. 
Viperin exerts anti-viral activity against Hepatitis C virus by promoting the degradation of 
NS5A in the replication complex. In contrast, NS5A reduces the catalytic activity of 
viperin, decreasing ddhCTP levels.  Membrane localization of viperin, NS5A and proviral 
adaptor protein VAP-33 is crucial for the interactions between these proteins. 
 
3.4 Experimental Procedure 
Cell lines The HEK293T cell line was obtained from ATCC. E. Coli strain BL21(DE3) was 
acquired from New England Biolabs.  
Plasmids Synthetic genes encoding human viperin (GenBank accession numbers 
AAL50053.1) were purchased from GenScript and sub-cloned into the pcDNA3.1(+) 
vector (Invitrogen). The primers for the pcDNA3.1(+)-viperin construct introduced an N-
terminal 3x-FLAG tag (DYKDHDGDYKDHDIDYKDDDDK) and a Kozak consensus 
sequence (5'-GCCAAC-3') for downstream protein expression in eukaryotic cells. An 
additional construct of viperin, truncating the first 50 amino acids from the full length 
construct, was cloned into pcDNA3.1(+) between HindIII and EcoRI sites, using Gibson 
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Assembly (New England Biolabs). The point mutations described herein were introduced 
using the QuikChange site-directed mutagenesis kit (Agilent Technologies, Mississauga, 
ON). The gene encoding the NS5A (genotype 1b) protein was obtained from AddGene 
as the pCMV-Tag1-NS5A plasmid and was sub-cloned into the pcDNA3.1(+) vector with 
N-terminal Myc-tag (EQKLISEEDL) using Gibson Assembly. The VAP-33 construct (VAP-
33C, VAP-33 residues 156-242) with N-terminal 3x-FLAG tag in pcDNA3.1(+) was a kind 
gift from professor Zhenghong Yuan, Fudan University, Shanghai, China(1).  
For expression of vipeirn in E. coli, a codon-optimized gene encoding viperin in pET28a 
vector lacking the first 50 amino acids of the N-terminal amphipathic alpha helix (viperin-
ΔN50, residues 50-361) was purchased from Genscript. Viperin-ΔN50 was sub-cloned 
into pRSFDuet-1 using the MfeI and HindIII restriction sites with a C-terminal 6x-His tag 
using Gibson Assembly. For expression of recombinant NS5A in E.Coli, a codon-
optimized NS5A gene, lacking first 39 amino acids of N-terminal amphipathic helix (NS5A-
ΔN39, residues 39-447), housed in pET52b(+) was purchased from Genscript. NS5A-
ΔN39 was sub-cloned downstream of maltose binding protein (MBP) in pMALc5x 
between the NdeI and HindIII restriction sites, using Gibson Assembly. This added a 
tobacco etch virus (TEV)-cleavable MBP tag to the N-terminus with a non-cleavable 6x-
His tag (encoded in the downstream primer) on the C-terminus of NS5A. The pMALc5x 
and pRSFDuet-1 vectors were obtained from GenScript. All sequences were confirmed 
at the University of Michigan Biomedical Research Core Facilities Advanced Genomics 
Core.   Recombinant human VAP-33 protein (VAP-33-ΔC20, residues 1-227) with an N-
terminal 6x-His tag was purchased from IBL America (catalog number IBATGP0471).  
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 Cell Culture and Transfection The pcDNA3.1(+) encoded constructs were 
overexpressed in HEK293T cells (cultivated in DMEM supplemented with 10% FBS and 
1% antibiotics) through transient transfection using polyethyleneimine transfecting agent. 
Co-transfection of two or more DNA constructs, allowing co-expression of viperin and its 
target proteins within the HEK293T cells, was performed using the same transfection 
protocol. Briefly, 20 µg of the respective plasmid DNA construct was mixed with 
polyethyleneimine at a 1:2 ratio, incubated at room temperature for 10 minutes, and then 
added to HEK293T cells at 50-60% confluence on a 100-mm dish. The transfected cells 
were then grown for up to 36 hours, gently pelleted, and stored at -80 °C until use. 
Antibodies Rabbit polyclonal RSAD2/ viperin antibody (11833-1-AP) and mouse 
monoclonal viperin (MABF106) were obtained from Protein Tech and EMD Millipore 
respectively. Mouse monoclonal anti-NS5A antibody was purchased from Virogen (256-
A). Goat anti-rabbit (170-6515) and anti-mouse (626520) Ig secondary antibodies were 
purchased from BioRad and Life Technologies respectively. Rabbit polyclonal GAPDH 
(10494-1-AP) was purchased from Proteintech and mouse monoclonal GAPDH antibody 
(6C5) was obtained from EMD Millipore. Mouse monoclonal anti-FLAG® M2 antibody 
(F1804) and 6x-His tag monoclonal antibody (MA1-135) were purchased from Sigma-
Aldrich and ThermoFisher Scientific. Goat anti-mouse IgG (H+L)-HRP conjugate 
secondary antibody (catalog number 626520) and goat anti-rabbit IgG (H+L)-HRP 
conjugate secondary antibody (catalog number 1706515) were purchased from 
ThermoFisher Technologies and Bio-Rad, respectively.  
Reagents S-(5′-Adenosyl)-L-methionine p-toluenesulfonate salt (≥80% (HPLC), 25 MG-
A2408), 5’-deoxyadenosine (D1771-25MG) was purchased from Sigma-Aldrich. Sodium 
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Hydrosulfite (7775-14-6, 100g) and DTT (DSD11000-25 MG) were purchased from Fisher 
Scientific and DOT Scientific Inc. respectively. MG-132 10 mM solution in DMSO, 1 mL 
(A11043) was purchased from AdooQ Bioscience. Nucleotide substrates CTP (Cytidine 
5'- triphosphate, disodium salt hydrate, 95%) were purchased from Acros Organics-
226225000. Pierce™ protein A/G plus agarose resin and control agarose resin (Pierce 
classic IP kit 26146) were purchased from ThermoFisher Scientific. Transfection Grade 
Linear Polyethylenimine Hydrochloride (MW 40,000) (Catalog No. 24765-1) was 
purchased from Polysciences, Inc. for DNA transfection in HEK293T cells. For in vitro 
chemical crosslinking experiment, bis(sulfosuccinimidyl)suberate or (BS3) (catalog 
number 21580) was purchased from Thermo Fisher Scientific. 
Immunoblotting Cells were lysed in lysis buffer (20 mM Tris, pH 7.5, 1% NP-40, 150 mM 
NaCl, 1 mM EDTA, 1 mM Na3VO4, and 10 mM β-glycerophosphate with SIGMAFASTTM 
Protease Inhibitor Tablets, S8830; Sigma). Supernatants of lysates were collected and 
mixed with 4x Laemmli sample buffer and 2-mercaptoethanol. The total amount of protein 
in lysates was determined by DC™ Protein Assay (5000116, Biorad). The supernatants 
were separated on 10% SDS-PAGE gels and transferred to PVDF membrane. 
Membranes were blocked for 1 h at room temperature in TBST buffer (20 mM Tris, pH 
7.5, 137 mM NaCl, and 0.1% Tween 20) containing 5% nonfat dry milk, followed by 
overnight incubation at 4°C in TBST buffer containing 5% nonfat dry milk and the 
appropriate primary antibody. Membranes were washed three times in TBST and then 
incubated for 1 h at room temperature with the secondary IgG-coupled horseradish 
peroxidase antibody. Primary antibodies were used at the following dilutions: viperin 
constructs - rabbit polyclonal diluted 1:2500, GAPDH - rabbit polyclonal diluted 1:5000, 
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NS5A - mouse monoclonal diluted 1:5000, anti-FLAG - mouse monoclonal diluted 1:3000, 
and anti-His - mouse monoclonal diluted 1:3000. Secondary antibodies were used at the 
following dilutions: goat anti-mouse diluted 1:5000 and goat anti-rabbit diluted 1:5000. 
The membranes were washed three times with TBST, and the signals were visualized 
with enhanced chemilluminescence reagent. Band intensities quantified using a Bio-Rad 
ChemiDoc Touch imaging system. Integrated density measurements were done using 
ImageJ software. Quantitative measurements of protein expression levels reported here 
represent the average of at least three independent biological replicates. 
Co-immunoprecipitation Cells expressing viperin/ viperinΔ3C/viperin-ΔN50, NS5A and 
VAP-33C from 100 mm tissue culture plate were rinsed twice with ice-cold PBS, 
harvested in lysis buffer (20 mM Tris, pH 7.5, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 
mM Na3VO4, and 10 mM β-glycerophosphate with EDTA-free protease inhibitor cocktail 
from Sigma), incubated on ice for 20 minutes and briefly sonicated. Lysates were 
collected by centrifugation at 13,000 × g for 15 minutes at 4°C and pre-cleared with 20 µl 
Pierce Control Agarose Resin. Lysates containing bait protein viperin/ viperinΔ3C/TN50-
vip were incubated with rabbit polyclonal anti-viperin antibody for 1 h at 4°C with end-to-
end rotation. The protein-antibody-complexes were incubated with pre-equilibrated 
Pierce protein A/G plus agarose resin at the ratio of suspension to packed gel volume 4:1 
for 1 h at 4°C by end-to-end rotation. Lysates containing prey protein NS5A and VAP-
33C were incubated with bait proteins at 1:1:1 total protein ratio for 30 minutes at 4°C. 
Flow-through was collected by gravity flow using Pierce gravity –flow columns and 
washed three times with wash buffer (20 mM Tris, pH 7.5, 1% NP-40, 150 mM NaCl, 1 
mM EDTA, 1 mM Na3VO4, and 10 mM β-glycerophosphate). Immuno-complexes were 
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eluted by boiling in 1x SDS-PAGE sample buffer and immunoblotted with the appropriate 
antibodies.  
Immunofluorescence HEK293T cells were grown to 30% confluence on poly-L-lysine- 
coated coverslips and then transiently transfected with wild-type viperin, viperinΔ3C, 
NS5A and VAP-33C plasmid DNA. After 36 hours of transfection, the cells were fixed with 
1% paraformaldehyde, permeabilized with 0.05% Triton X-100 dissolved in PBS, and 
washed three times with PBS containing 0.1% Tween20. The fixed cells were stained 
with the appropriate antibodies after blocking with 1% FBS in PBS. Primary antibodies 
were diluted in PBS containing, 1% FBS and stained with rabbit polyclonal anti-viperin 
(Proteintech) and mouse monoclonal anti-NS5A (Virogen) antibodies at 1:500 dilution. 
After incubation at 4°C overnight, the coverslips were washed with PBS containing 0.1% 
Tween20 and treated with Alexa Fluor 647-conjugated goat anti-mouse (Life 
Technologies) and Alexa Fluor 488-conjugated goat anti-rabbit (Abcam) secondary 
antibodies at a dilution of 1:500 at room temperature for 2 hours. The coverslips were 
washed three times with PBS containing 0.1% Tween20 and mounted in ProLong™ Gold 
Antifade Mountant (Molecular Probes). Images were acquired with an Olympus IX81 
microscope with 60x objective. The images were processed with ImageJ software.  
Reductive SAM assay of viperin HEK293T cells transfected with viperin or viperinΔN50, 
and/or NS5A and VAP-33C were harvested from one 100-mm diameter tissue culture 
plate each, re-suspended in 500 µl of anoxic Tris-buffered saline (50 mM Tris-Cl, pH 7.6, 
150 mM NaCl) containing 1% Triton X-100, sonicated within an anaerobic glovebox (Coy 
Chamber), and centrifuged at 14,000 g for 10 min. Dithiothreitol (DTT; 5 mM) and 
dithionite (5 mM) were added to the cell lysate together with CTP (300 μM). The assay 
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mixture was incubated at room temperature for 30 min prior to starting the reaction by the 
addition of SAM (200 µM). The assay was incubated for 60 min at room temperature, 
after which the reaction stopped by heating at 95 °C for 10 min. The solution was chilled 
to 4 °C, and the precipitated proteins were removed by centrifugation at 14,000 rpm for 
25 min. The supernatant was then extracted with acetonitrile. Samples were analysed in 
triplicate by UPLC-tandem mass spectrometry (25).  
NS5A-ΔN39 in vitro expression and purification MBP_NS5A-ΔN39 was transformed 
into BL21(DE3) chemically competent cells and plated on ampicillin (AMP) supplemented 
LB-agar plates. The following day, a single colony was picked and added to 2-25mL 
fractions of AMP-supplemented LB media and shaken overnight at 37°C. The seed 
cultures were added to 2L of 2xYT media supplemented with AMP and 1% glycerol. The 
culture was shaken for approximately 3 hours, until mid-log was achieved (O.D.600 ≈ 0.8), 
then cold shocked by incubation at 4°C for one hour. 0.5 mM IPTG was added and the 
culture was grown at 16°C overnight. The cells were centrifuged and the pellet was 
harvested and stored at -80°C. 
The cell pellet was re-suspended at a ratio of 30 mL/ 2L culture in NS5A lysis buffer 
(26)(50 mM Tris pH 8.0, 200 mM NaCl, 10 mM imidazole, 5% glycerol, 2 mM L-Cysteine 
– HCl, 2 mM 2-mercaptoethanol) supplemented with 1 cOmpleteTM EDTA-free protease 
inhibitor cocktail tablet. The cell suspension was lysed on ice via sonication at amplitude 
8 in 20 second intervals for a total process time of 4 minutes. The lysate was centrifuged 
for 45 min at 12,000 RPM. 1 mL of 100% Ni-NTA resin (pre-equilibrated with lysis buffer) 
was added to the supernatant and incubated at 4°C for 2 hr. The mixture was added to a 
20 mL fritted column and the flow-through was collected and set aside. The column was 
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washed with 30 column volumes of lysis buffer supplemented with 25 mM imidazole. The 
protein was eluted from the Ni-NTA using three - 10 column volume washes of lysis buffer 
supplemented with 100, 200, or 300 mM imidazole. The lysate, pellet, supernatant, flow 
through, wash, and all elutions were analysed via reducing sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS-PAGE).  
NS5A-ΔN39 TEV cleavage and size exclusion chromatography Once presence and 
purity of the protein was confirmed, the appropriate elution fraction was subjected to TEV 
cleavage. The reaction contained approximately 10-15 mg of pure MBP_NS5A-ΔN39, 50 
μg TEV, and 3 mM DTT, was carried out overnight (18-20 hours) at 4°C, and the cleaved 
protein was purified over a pre-packed 5 mL MBP-trap column (from GE). The reaction 
was circulated over the column via peristaltic pump at 0.5 mL/min three times and the 
flow through, which contained cleaved NS5A, was collected after a fourth pass. The 
column was washed with 10 column volumes of NS5A storage buffer (50 mM Tris pH 8.0, 
150 mM NaCl, 10% glycerol). Any un-cleaved protein was eluted with 5 column volumes 
of NS5A storage buffer supplemented with 10 mM maltose.  
Next, a size exclusion step was added in order to remove any soluble aggregate and 
additional protein contaminants not removed by the post-TEV cleavage purification. 
Cleaved NS5A-ΔN39 was concentrated down to approximately 3 mL and injected onto a 
pre-equilibrated prep-grade Superdex-200 size exclusion column. The column was 
washed with NS5A storage buffer without glycerol at 1 mL/min. Elution fractions were 
compared against a 15-600 kDa protein standard (Millipore Sigma) and analysed via 
SDS-PAGE for purity and presence of soluble, cleaved NS5A-ΔN39. These fractions 
were concentrated and buffer exchanged using a PD-10 desalting column into NS5A 
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storage buffer. This was concentrated further to 500 μL (final concentration ~ 38 μM), 
aliquoted, and flash frozen for future use. Protein concentration was estimated via Abs280 
and confirmed with gel quantification.  
Viperin-ΔN50 in vitro expression and purification Viperin-ΔN50 was expressed in the 
same manner as described above with small differences. pRSFDuet-1 is kanamycin 
(KAN) resistant, so all antibiotic selection steps were done with KAN. Once the culture 
entered mid-log phase, it was equilibrated to 18°C after which 0.2 mM Na2S · 9H20 was 
added. After 20 additional minutes of equilibration, 0.2 mM FeCl3 and 0.1 mM IPTG were 
added and the culture was shaken overnight at 16°C. Cells were harvested by 
centrifugation the following day and stored at -80°C. 
The purification was carried out in the same manner as above, with small differences. All 
purification steps were done in an anaerobic environment (Coy chamber) using anoxic 
(nitrogen flushed) buffers (viperin-ΔN50 lysis buffer contained 50 mM HEPES pH 7.5, 
300mM NaCl, and 5% glycerol). Once the lysate had been cleared via centrifugation it 
was added to a pre-packed 5 mL His-Trap column (from GE) via peristaltic pump. The 
solution was flowed over the column 3x at 0.5 mL/min and the flow through was collected 
on the fourth pass. The column was washed with 10 column volumes of viperin-ΔN50 
lysis buffer supplemented with 50mM imidazole. viperin-ΔN50 was eluted with three 15 
mL washes of lysis buffer supplemented with 200 mM imidazole. Protein presence and 
purity was analysed in the same manner as above. Once confirmed, the appropriate 
elution fraction was concentrated, buffer exchanged into viperin storage buffer (50mM 
Tris pH 8.0, 150 mM NaCl, 10% glycerol) with a PD-10 desalting column, and stored on 
ice before reconstitution. 
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Reconstitution of viperin-ΔN50 [4Fe-4S] cluster The reconstitution of the [4Fe-4S] 
cluster in the purified viperin-ΔN50 was performed in an anaerobic environment (Coy 
chamber, O2 levels kept below 20 ppm)(21). Purified protein was incubated with 5 mM 
DTT for 20 min on cold beads. The stock solution of 0.1 M FeCl3 and 0.1 M Na2S was 
added drop-wise, incubating for 10 min after each addition until the protein turned dark 
brown in color. A 10 mL PD-10 desalting column was equilibrated with 2 column volumes 
of viperin storage buffer. The reconstituted protein (2.5 mL) was then added to the 
equilibrated PD-10 column and eluted with 3.5 mL of viperin storage buffer. The elution 
was then concentrated again using vivapore concentrators to the final volume of 1 mL. 
The concentrated protein (final concentration~ 68 μM) was aliquoted, flash frozen in liquid 
nitrogen, and stored at -80°C. 
Co-immunoprecipitation of recombinant NS5A and VAP-33 using recombinant 
viperin  All steps were performed inside anaerobic Coy chamber. Recombinant human 
viperin-ΔN50, purified from BL21 (DE3) E. Coli, was incubated with rabbit polyclonal anti-
viperin antibody for 1h at 4°C, at final concentration 0.5 μM, in the presence of dithiothritol 
(5 mM) and CTP (300 μM). The protein-antibody complex was incubated with pre-
equilibrated protein A/G beads (pre-blocked with 2mg/ml Bovine Serum albumin protein 
overnight at 4°C) for 1h at 4°C.  Recombinant prey proteins NS5A-ΔN39 and VAP-33-
ΔC20 were incubated with viperin-antibody-bead-complex at a final concentration of 1µM 
for 30 minutes at 4°C. Flow-through was collected using Pierce gravity columns and 
washed three times with 50 mM Tris, pH 7.5, 150 mM NaCl, 10% glycerol, 1.0% Tween-
20. Immuno-complexes were eluted by boiling in 1x SDS-PAGE sample buffer outside 
Coy chamber and immunoblotted with appropriate antibodies. 
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In vitro SAM cleavage assay  The reaction containing purified 5 uM viperin-ΔN50, 7.5 
uM NS5A-ΔN39 or VAP-33-ΔC20 or both in 50 mM tris-HCl pH 8.0, 150 mM NaCl, 10% 
glycerol, 5 mM DTT, 100 uM L-tryptophan (internal standard), and 300 uM CTP were 
incubated on cold beads for 2 hours under anaerobic conditions to allow for complex 
formation. The reactions were then incubated at 37°C for 5 minutes after the addition of 
5 mM dithionite. Finally, 200 uM SAM was added to each reaction and 20 uL aliquots 
were taken at various time intervals (0, 2, 4, 6, 8, and 10 minutes). Each sample was 
quenched with 20 uL of 50 mM H2SO4 solution. The samples were centrifuged at 14,000 
rpm for 10 minutes to precipitate protein before loading it on to a Vydac 201TP 10 µm 
C18 column (250 X 4.6 mm, 10 µm particle size). Buffer A was 0.01% TFA in DI water 
and buffer B was 0.01% TFA in acetonitrile. The flow rate was 1.0 ml/min and the following 
gradient was applied: 0% B for 0.01 minutes, 0-5% B from 0.01-5.01 minutes, 5% B from 
5.01-5.31 minutes, 5-75% B from 5.31-25.31 minutes, 75% B from 25.31-26.31 minutes, 
75-100% B from 26.31-27.01 minutes, 100% B from 27.01-32.01 minutes, 100-0% B from 
32.01-32.31 minutes, 0% B from 32.31-36.31 minutes. The internal standard peak (L-
tryptophan) was observed at 13.25 minutes and the 5’deoxyadenosine (5’dA) peak was 
observed at 10.10 minutes. The peaks were integrated using LCSolution software.  
In vitro chemical crosslinking To determine presence of a TN50-NS5A-VAP33 protein 
complex, chemical crosslinking via bis(sulfosuccinimidyl)suberate (BS3) was employed. 
This would allow for covalent tethering of nearby proteins with an 8-carbon spacer via 
exposed lysine residues using N-hydroxysulfosuccinimide (NHS) ester chemistry. 
Purified TN50, NS5A, and VAP33 were buffer exchanged in to crosslinking buffer (50 mM 
HEPES pH 7.5, 150 mM NaCl) and used at 10 uM (each) with a 35x molar excess of BS3 
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reagent. The proteins were incubated at 4°C for one hour before the addition of 
crosslinker. The reaction was allowed to proceed for two hours at 4°C before they were 
quenched with 100mM Tris pH 7.5. The reactions were analyzed via SDS-PAGE and 
Western Blot.  
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Activation of the Radical SAM Activity of Viperin through the 
Interplay of Innate-immune Signalling Proteins Kinase IRAK1 and 
Ubiquitin Ligase TRAF6 
 
(Work in this chapter is published in J. Biol. Chem. (2019), 294, 6888-6898) 
 
 
4.1 Introduction In addition to exerting antiviral activity against a diverse range of 
pathogens, viperin has also been found to directly modulate innate immunity signalling 
(1,2). Stimulation of T cells from viperin knockout mice resulted in a decrease in 
inflammatory cytokine production, ultimately affecting the viral DNA binding activity of NF-
kB signaling. This indicates that viperin plays a role in T cell activation (3). Viperin was 
also found to be involved in the Toll-like receptor signalling pathways (TLR7/9) to 
upregulate interferons, thereby, promoting the host defense response (4). As a part of 
innate immunity, Toll-like receptor 7 (TLR7) and TLR9 are among various pattern 
recognition receptors that sense viral nucleic acids and induce the production of type I 
interferons by plasmacytoid dendritic cells (pDCs) to protect the host from viral 
infection(5-7). The TLR7/9 signaling pathways were stimulated in these cells with either 
dsRNA or lipopolysaccharides to induce viperin expression (2,4,8). As a component of 
this pathway, viperin was shown to interact with two signal mediator proteins: interleukin-
1 receptor-associated kinase (IRAK1) and the E3 ubiquitin ligase, TRAF6. Viperin recruits 
IRAK1 and TRAF6 to lipid bodies and stimulates the K63-linked poly-ubiquitination of 
IRAK1 by the E3 ubiquitin ligase, TRAF6 (1,9). K63-linked poly-
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ubiquitination, in turn, activates IRAK1 to phosphorylate interferon regulatory factor 7 
(IRF7), causing IRF7 to migrate to the nucleus where it activates transcription of type 1 
interferons (9,10) [Figure. 4.1].   
Another adaptor protein, mitochondrial antiviral signaling protein (MAVS), involved in 
cytosolic RNA receptors RIG-I (retinoic acid-inducible gene I) and MDA5 (melanoma 
differentiation-associated protein 5), was also identified as a potential interacting partner 
of viperin (11,12). As a result of this interaction, viperin was observed to suppress the 
MAVS-dependent signaling pathway and act as a negative effector in IFNβ production.  
 
Figure 4.1: Interaction of viperin with kinase IRAK1 and E3 Ubiquitin ligase TRAF6 
in Toll-like receptor 7/9 pathway. Viperin facilitates the K63-linked ubiquitination of 
IRAK1 by TRAF6, thereby promoting IRAK1 activation. 
 
 
As viperin functions differently in controlling various signaling pathways, it proved difficult 
to provide a possible explanation for the molecular mechanism of viperin. Progress was 
made by the finding that the enzymatic activity of viperin involves producing the antiviral 
nucleotide ddhCTP from CTP (13). We anticipated that its enzymatic activity might be 
regulated by interactions with its partner proteins. To examine this possibility, we 
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reconstituted the interactions between viperin, IRAK1, and TRAF6 that lead to poly-
ubiquitination of IRAK1 in HEK293T cells. Our experiments demonstrate that IRAK1 and 
TRAF6 activate viperin towards reductive cleavage of SAM and the production of 
ddhCTP. At the same time, viperin stimulates the poly-ubiquitination of IRAK1 by TRAF6, 
in a manner that is SAM-dependent. The synergistic activation of these enzymes provides 
a mechanism to couple innate immune signaling to the production of antiviral 
ribonucleotides. The work was described this chapter was done collaboratively with Arti 
Dumbrepatil and published in J. Biol. Chem. (2019) , 294, 6888-6898. 
 
4.2 Results As full length viperin was unable to be expressed in E. coli, we decided to 
study the interactions between viperin, TRAF6 and IRAK1 in a cellular context.  
Expression of viperin, IRAK1 and TRAF6 in eukaryotic cells allowed viperin to localize to 
the endoplasmic-reticulum membrane and lipid droplets, and allowed the effect of viperin 
on the poly-ubiquitination of IRAK1 by TRAF6 to be examined.   
4.2.1 IRAK1 mediates interactions between Viperin and TRAF6.  To examine whether 
viperin, IRAK1 and TRAF6 form a complex, immunoprecipitation experiments were 
conducted using either FLAG-tagged viperin as bait and HA-tagged TRAF6 and Myc-
tagged IRAK1 as prey proteins. Immunoprecipitation experiments were conducted on 
HEK 293T cells transfected with all three proteins and with extracts of cells singly 
transfected with viperin, IRAK1 or TRAF6. For singly transfected cell extracts these were 
combined in a 1:1:1 ratio and incubated for 30 min at 4o C before being subjected to 
immunoprecipitation.  The bait protein was then immunoprecipitated with the appropriate 
antibody.  Both sets of experiments yielded similar results [Figure. 4.2]. 
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With viperin as bait, IRAK1 co-precipitated independently of TRAF6; however, TRAF6 
only co-precipitated in presence of both viperin and IRAK1 [Figure. 4.2].  These 
observations imply that IRAK1 binds to both TRAF6 and viperin to mediate complex 
formation, whereas viperin and TRAF6 do not independently associate with each other.  
Similar results were obtained when viperinΔ3C was used as the bait protein, which 
suggests that the iron-sulfur cluster is not crucial for IRAK1 to bind viperin.  
 
Figure 4.2: IRAK1 mediates formation of the complex between viperin, IRAK1 and 
TRAF6. Immuno-tagged genes were expressed into HEK 293T cells and viperin was 
immunoprecipitated with anti-FLAG antibody after incubating with IRAK1 or TRAF6 or 
both. Immunoblotting against IRAK1 and TRAF6 showed the complex formation among 
these proteins. Mutations in the radical SAM domain (viperinΔ3C) do not affect ability of 




The N-terminal domain of viperin serves to localize the enzyme to the cytoplasmic face 
of lipid droplets and the ER (14), whereas TRAF6 and IRAK1 are cytosolic enzymes (15).  
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Consistent with the immunoprecipitation results, we observed that co-expression of 
viperin with TRAF6 and IRAK1 caused these enzymes to re-localize to the ER membrane 
as determined by immuno-fluorescence microscopy of fixed and immuno-stained cells 
[Figure. 4.3].  
 
Figure 4.3: Relocalization of IRAK1 and TRAF6 to the endoplasmic reticulum by 
viperin. HEK293T cells were transfected with viperin, IRAK1 and TRAF6 and immune-
stained for the proteins. Top panels: cells co-transfected with IRAK1 (red) and TRAF6 
(green) show diffuse expression throughout the cell. Middle panels: cells were co-
transfected with IRAK1, TRAF6 and viperin. Staining for viperin (green) and IRAK1 (red) 
demonstrates co-localization (yellow) of viperin and IRAK1. Bottom panels: cells were co-
transfected with IRAK1, TRAF6 and viperin. Staining for viperin (green) and TRAF6 (red) 
demonstrates co-localization (yellow) of viperin and TRAF6. Co-expression of IRAK with 
viperin appears to result in IRAK1 also forming punctate structures that do not co-localize 
(middle panels).  Scale bar = 5 µm. The figure is reproduced from J.Biol. Chem. (2019) 
294, 6888-6898. 
  
4.2.2 IRAK1 and TRAF6 synergistically activate viperin.  As enzymes in signaling 
pathways typically function by activating or repressing the activity of other enzymes, the 
involvement of viperin in the TLR7/9 signaling pathways suggested that the enzymatic 
85 
 
activity of viperin may be regulated by IRAK1 and/or TRAF6. Therefore, as viperin was 
confirmed to form a complex with these Toll-like receptor signalling enzymes, we 
examined the effects of IRAK1 and TRAF6 co-expression on the enzymatic activity of 
viperin to produce 5’-deoxyadenosine. Cell extracts were prepared under anaerobic 
conditions (due to the in vitro oxygen-sensitivity of radical SAM enzymes) from HEK 293T 
cells co-transfected with viperin, IRAK1 and TRAF6. The enzymatic activity of viperin was 
quantified by measuring the formation of 5'-dA, and the specific activity was measured 
based on the amount of viperin present in the cell extracts, quantified by immunoblotting 
[Fig. 4.4(A)].  
When assayed in the absence of exogenous CTP, cell extracts expressing only viperin 
exhibited low levels of activity to produce 5’-deoxyadenosine, with an apparent turnover 
number, kobs = 0.94 ± 0.05 h-1 [Figure. 4(B), Appendix A.3].  This basal activity is likely 
due to low concentrations endogenous CTP in the cell extract.  Negligible amounts of 5'-
dA were formed in cell extracts lacking viperin or in cells expressing viperinΔ3C. 
Surprisingly, when the co-substrate CTP (300 μM) was added to the assay, only a modest 
2.4-fold increase in activity (kobs = 2.38 ± 0.05 h-1) was observed.  In contrast, when 
lysates prepared from cells co-expressing IRAK1 and TRAF6 were assayed, viperin 
activity with CTP as substrate increased ~10-fold (Fig. 4.4B).  Under these conditions 
kobs = 21.4 ± 1.6 h-1, which is 2-fold higher than the apparent kcat reported for truncated 
rat viperin (13).  In the absence of exogenous CTP, the basal level of viperin activity was 
increased 4-fold (kobs = 4.30 ± 0.21 h-1) by co-expression with IRAK1 and TRAF6, 
consistent with these proteins activating viperin.  Expression of viperin with IRAK1 alone 
resulted in lower levels of activation, whereas co-expression of viperin with TRAF6 alone 
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had no effect on viperin activity. These results suggested that IRAK1 and TRAF6 
synergistically activate viperin to produce 5’-deoxyadenosine, and concommitently 
formation of ddhCTP from CTP, through radical SAM cleavage activity. 
 
Figure 4.4: IRAK1 and TRAF6 synergistically activate viperin. Reductive SAM 
cleaving activity of viperin, expressing in HEK293T cells viperin with IRAK1 and TRAF6, 
was measured by monitoring the amount of 5’-deoxyadenosine produced over 1 h. (A) 
Immunoblot showing the expression level of viperin, co-expressed with IRAK1 and/or 
TRAF6. The relative expression levels were determined by normalizing to GAPDH, used 
as the internal loading control. (B) The amount of 5'-dA formed in 1 h, normalized for the 
amount of viperin present in the cell extracts, is plotted relative to the viperin-only sample 
= 1.0. The data represent the mean and standard deviation of three independent 
biological replicates with three technical replicates of each measurement. The figure is 
reproduced from J.Biol. Chem. (2019) 294, 6888-6898. 
 
 
4.2.3 Ubiquitination of IRAK1 requires viperin. Given that IRAK1 and TRAF6 appeared 
to activate viperin towards the production of ddhCTP, we were interested to know 
whether, conversely, viperin stimulated the ubiquitination of IRAK1 by TRAF6.   
To identify the ubiquitinated isoforms of IRAK1, it was immune-precipitated from 
HEK293T cell extracts and the recovered protein then analyzed by immunoblotting with 
anti-ubiquitin antibodies. High molecular weight isoforms of IRAK1 were observed in the 
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immunoblots, especially in both situation when IRAK1 was transfected with viperin and 
TRAF6 or viperin only [Figure. 4.5]. This result confirmed that viperin specifically 
stimulates IRAK1 ubiquitination. In contrast, the inactive viperinΔ3C mutant failed to 
stimulate ubiquitination of IRAK1 [Figure. 4.5]. 
Interestingly, co-expression of TRAF6 with viperin did not change the level of IRAK1 
ubiquitination significantly [Figure. 4.5]. This suggests that the complex of viperin with 
IRAK1 either recruits endogenous TRAF6 and/or other E3 ubiquitin ligases to ubiquitinate 
IRAK1 (4,10).  Overall, the fraction of over-expressed IRAK1 converted to high molecular 
weight isoforms remained relatively small. This observation reflects the fact that 
ubiquitination is dynamic processes in which de-ubiquitination pathways also operate; 
furthermore, the high, non-physiological concentrations of IRAK1 produced by 
transfection may exceed the capacity of the cellular ubiquitination machinery. 
 




Figure 4.5: Viperin stimulates ubiquitination of IRAK1. HEK293T cells were 
transfected with genes encoding IRAK1, TRAF6, viperin or viperinΔ3C as indicated.  Left 
panel: IRAK1 was immunoprecipitated as bait protein and immunoblotted with anti-
ubiquitin antibody. GAPDH was used as a loading control. Right panel: Quantification of 
ubiquitination of IRAK1 using ImageJ software, normalized to GAPDH.   Statistical 
analyses were presented as mean +/− S.E.M. (n = 3) with *** indicating p < 0.001, 
(Student's t-test for independent samples). The figure is reproduced from J.Biol. Chem. 
(2019) 294, 6888-6898. 
 
4.3 Discussion A number of studies suggest that interactions between viperin and a 
variety of host and viral proteins are important for its antiviral effects (16,17) (18) (19) (20) 
(21) (22), although the evidence has tended to rely on indirect measures of viperin’s 
activity such as the reduction of viral titre or viral RNA levels.  Furthermore, in several 
cases the radical SAM activity of viperin appears to be dispensable for its antiviral activity 
(17,19,23).  The discovery that viperin catalyzes the synthesis of ddhCTP (13) provided 
an important advance in our understanding of the mechanism by which viperin exerts its 
antiviral effects.  Therefore, we took an enzymatic approach to decipher the mechanism 
how viperin interact with its target-proteins to impart antiviral activity. By reconstituting the 
interactions between viperin, IRAK1 and TRAF6 in HEK 293T cells, we have been able 
to examine a specific, biochemically well-defined function of viperin: the activation of 
IRAK1 by poly-ubiquitination.  This finding underscores the necessity of the interaction 
between viperin, IRAK1 and TRAF6 for ubiquitination of IRAK1 to occur.  
Given viperin’s role as a component of the TLR7/9 signaling pathways, it might be 
expected that other proteins in the pathway would regulate its enzymatic activity. Our 
studies show that the enzymatic activity of viperin to produce 5’-deoxyadenosine is 
increased by ~10-fold by co-expression with IRAK1 and TRAF6, whereas IRAK1 is not 
efficiently ubiquitinated in vivo unless viperin is also co-expressed.  Thus, the activities of 
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viperin and IRAK1 appear to be synergistically regulated activities, mediated through 
protein-protein interactions between viperin, IRAK1 and TRAF6.  The Fe-S cluster is 
required for viperin to catalyze the formation of ddhCTP; however, we have shown that 
the radical-SAM activity is not critically required for viperin to stimulate IRAK1 
ubiquitination, as the poly-ubiquitinated IRAK1 isoforms were observed when co-
expressed with viperinΔ3C. Also, IRAK1 and TRAF6 formed the protein-complex in the 
presence of the radical SAM domain-mutant viperin.    
Based on these observations we suggest that the reductive cleavage of SAM, and 
concomitant formation of ddhCTP, may serve as a mechanism by which viperin could 
regulate the ubiquitination of IRAK. We propose that in the absence of SAM, viperin 
adopts a conformation that is unable to stimulate ubiquitination of IRAK1.  Upon binding 
SAM, viperin undergoes a conformational change to an active state that stimulates K63-
linked poly-ubiquitination of IRAK1 by TRAF6 (or other E3 ligases), eventually leading to 
transcription of type I interferons (4).  Once the complex between IRAK1, TRAF6 and 
viperin is formed, viperin is activated to cleave SAM, thereby initiating the catalytic cycle 
leading to the formation of ddhCTP and 5’-dA.  Completion of the catalytic cycle returns 
viperin to its inactive state, preventing further poly-ubiquitination of IRAK1. 
Our measurements of viperin activity to produce 5’-deoxyadenosine in cell extracts 
indicate that viperin converts CTP to ddhCTP with kobs, = 21.4 ± 1.6 h-1, which is about 
twice as fast as in vitro kinetic data reported previously (13), but still rather slow by 
comparison with most enzyme reactions.  However, the slow kinetics of viperin make this 
reaction well suited to regulate a signaling pathway in a manner analogous to signal 
regulation by hetero-trimeric G proteins (24,25).  We note that; although consistent with 
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our data, further studies with purified enzymes will be needed to validate this mechanistic 
proposal, which would constitute a new mode of regulating cellular protein activity by 
radical-SAM enzymes. 
In conclusion, our experiments provide evidence for a regulatory mechanism that links 
the production of the newly identified antiviral nucleotide, ddhCTP, by viperin to 
transduction of innate immune signaling through K63-linked polyubiquitination of IRAK1 
by TRAF6.  In this manner, the up-regulation of various proteins that constitute the cellular 
antiviral response is coordinated with the production of a small molecule inhibitor of viral 
replication.  Protein ubiquitination plays multiple roles in cellular proteostasis and signal 
transduction (26,27).  We suggest that the wide-ranging roles that viperin plays in the 
antiviral response may, in part, result from the ability of the enzyme to recruit and activate 
a subset of the many E3 ubiquitin ligases present in the cell to ubiquitinate target proteins, 
thereby regulating their cellular levels in response to viral infection.  
 
 
4.4 Experimental Procedures 
Cell lines  The HEK293T cell line was obtained from ATCC.   
Antibodies  Rabbit polyclonal RSAD2/ Viperin antibody (11833-1-AP) was obtained from 
Protein Tech.  Rabbit polyclonal IRAK1 antibody (PA5-17490) was obtained from Thermo 
Scientific.  Rabbit polyclonal Ubiquitin antibody (sc-9133) and mouse monoclonal TRAF6 
antibody (sc-8409) were purchased from Santa Cruz.  Goat anti-rabbit (170-6515) and 
anti-mouse (626520) Ig secondary Abs were purchased from BioRad and Life 
Technologies respectively. Rabbit polyclonal GAPDH (TAB1001) was purchased from 
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Thermo Scientific and Mouse monoclonal GAPDH antibody (6C5) was obtained from 
EMD Millipore. 
Plasmids  Synthetic genes encoding human viperin, IRAK1 and TRAF6 (GenBank 
accession numbers AAL50053.1, NM145803, NM001569 respectively) were purchased 
from GenScript.  For details see supplementary information. 
Reagents  The sources of other reagents were as described previously (17)..  Nucleotide 
substrates: Cytidine 5'-triphosphate, disodium salt hydrate, 95%; were purchased from 
Acros Organics (226225000). Pierce™ Anti-c-Myc Magnetic Beads (88842) were 
purchased from ThermoFisher Scientific. 
Transfection HEK 293T cells, cultured as described above, were transiently transfected 
using FuGENE® HD (Promega) following the manufacturer’s instructions. 
Immunofluorescence analyses  Cells were grown on poly-L-lysine-coated coverslips to 
30–40% confluence, transfected with plasmids expressing Viperin, IRAK1 and/or TRAF6 
and incubated for 30 h. Cells were fixed with 4% paraformaldehyde, permeabilized with 
0.05% Triton X-100 dissolved in PBS, and washed three times with PBS containing 0.1% 
Tween20.  The fixed cells were stained with the appropriate antibodies.  Primary 
antibodies were diluted in PBS containing, 1% FBS and 0.1% Tween 20. Viperin was 
detected by using mouse monoclonal anti-viperin (Abcam) diluted 1:250, and calnexin 
was detected with rabbit polyclonal antibody (Abcam) diluted 1:250. IRAK1 was detected 
by using rabbit polyclonal IRAK1 antibody (Thermo Scientific) diluted 1:250 and mouse 
monoclonal c-Myc Tag antibody (Thermo Scientific) diluted 1:100.  TRAF6 was detected 
by using mouse monoclonal TRAF6 antibody (Santa Cruz) diluted 1:100. After incubation 
at room temperature for 1 h or overnight at 4°C, the coverslips were washed with PBS 
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containing 0.1% Tween20 and treated with Alexa Fluor 647-conjugated goat anti-mouse 
(Life Technologies) and Alexa Fluor 488-conjugated goat anti-rabbit (Abcam) secondary 
antibodies at a dilution of 1:400 at room temperature for 2 h.  The coverslips were washed 
three times with PBS containing 0.1% Tween20 and mounted in ProLong™ Gold Antifade 
Mountant (Molecular Probes). Images were acquired with an Olympus IX81 microscope 
with a 60× 1.49NA objective on an Andor iXON Ultra EMCCD camera.  488 nm (Coherent 
Cube 488-50) and 640 nm (Coherent Cube 640–100) laser excitation was aligned in HILO 
imaging mode for axial sectioning using an Olympus cell^TIRF module.  
Immunoblotting Cells were lysed in TBST buffer (20 mM Tris (pH 7.5), 500 mM NaCl, 
0.05% Tween-20) containing protease inhibitors (SIGMAFASTTM Protease Inhibitor 
Tablets, S8830; Sigma). Supernatants of lysates were collected and mixed with reducing 
sample buffer. The supernatants were separated on 10% SDS-PAGE gels. The 
bicinchoninic acid (BCA) assay (Thermo Scientific) was used to determine the total 
amount of protein in the lysates. Immunoblotting was performed as describes previously 
(17). Primary antibodies used were directed against viperin (rabbit polyclonal diluted 
1:2500), GAPDH (rabbit polyclonal diluted 1:5000), IRAK1 (rabbit polyclonal diluted 
1:4000), TRAF6 (mouse monoclonal diluted 1:500) and GAPDH (mouse monoclonal 
diluted 1:5000). Rabbit polyclonal ubiquitin antibody was used at a dilution of 1:1000. 
Blots were visualized, and band intensities quantified using a Bio-Rad ChemiDoc Touch 
imaging system. Integrated density measurements were done using ImageJ software. 
Quantitative measurements of protein expression levels reported here represent the 
average of at least three independent biological replicates. 
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Immunoprecipitation Assays  Cells were rinsed twice with ice-cold PBS, harvested in P40 
lysis buffer (50 mM Tris, pH 7.4, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM 
EDTA, 10 mM NaF, and 0.2 mM phenylmethylsulfonyl fluoride with protease inhibitor 
cocktail from Sigma), and briefly sonicated. Lysates were collected by centrifugation at 
12,000 × g for 15 minutes at 4°C. For immunoprecipitation, ratio of suspension to packed 
gel volume was 2:1. Resin pre-equilibration was done as per the manufacturer’s protocol. 
Three hundred microliters of a 1:1:1 ratio of cell lysates was added and incubated for 16 
hours at 4°C with gentle rotation. Beads were pelleted by centrifugation at 5,000 × g for 
30 seconds at 4°C and washed three times with washing buffer (50 mM Tris, pH 7.4,150 
mM NaCl, 10% glycerol, 1 mM EDTA, 10 mM NaF, and 0.2 mM phenylmethylsulfonyl 
fluoride with protease inhibitor cocktail from Sigma). Immunocomplexes were eluted by 
boiling in SDS-PAGE sample buffer, separated by SDS-PAGE, and transferred to a 
nitrocellulose membrane. Immunoprecipitation using Protein A beads or anti Myc-tagged 
magnetic beads was performed as per the manufacturers protocol. Membranes were 
blocked for 2 h at room temperature in TBST buffer (20 mM Tris, pH 7.5, 137 mM NaCl, 
and 0.1% Tween 20) containing 5% nonfat dry milk, followed by overnight incubation at 
4°C in TBST buffer containing 3% nonfat dry milk and the appropriate primary antibody. 
Membranes were washed three times in TBST and then incubated for 2 h at room 
temperature with the secondary IgG-coupled horseradish peroxidase antibody. The 
membranes were washed three times with TBST, and the signals were visualized with 
enhanced chemiluminescence reagent as described in immunoblotting. 
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Statistical analyses  Results from all studies were compared with unpaired two-tailed 
Student's t test using GraphPad Prism 5 software. P values less than 0.05 were 
considered significant. 
Assay of viperin in HEK 293T cell lysates  HEK 293T cells transfected with viperin, and/or 
IRAK1 and TRAF6 were harvested from one 10 cm diameter tissue culture plate each, 
resuspended in 500 µl of anoxic Tris-buffered saline (50 mM Tris-Cl, pH 7.6, 150 mM 
NaCl) containing 1% Triton X-100, sonicated within an anaerobic glovebox (Coy 
Chamber), and centrifuged at 14,000 g for 10 min. Dithiothreitol (DTT; 5 mM) and 
dithionite (5 mM) were added to the cell lysate together with CTP (300 μM). The assay 
mixture was incubated at room temperature for 30 min prior to starting the reaction by the 
addition of SAM (200 µM). The assay was incubated for 60 min at room temperature, 
after which the reaction stopped by heating at 95 °C for 10 min. The solution was chilled 
to 4 °C, and the precipitated proteins were removed by centrifugation at 14,000 rpm for 
25 min. The supernatant was then extracted with acetonitrile. Samples were analyzed in 
triplicate by UPLC-tandem mass spectrometry as described previously (17). For details 
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 Proteomics Analysis of Viperin and Identification of its 
Interactome 
 
5.1 Introduction. The Eukaryotic cells undergo various spatial and temporal changes in 
organelle morphology and protein distribution upon viral infection. Viruses exploit the host 
proteome organization at different stages of viral replication, from viral entry to egress. 
With advances in microscopy and mass-spectrometric techniques, viruses have been 
shown to rely on the organization and morphology of host cell organelles and induce 
changes in the abundance of cellular proteins (1).  The endoplasmic reticulum is one of 
the crucial membranous networks that has been co-opted by viruses to facilitate viral 
repication (2). Viruses manipulate the cellular protein folding and misfolding machinary, 
emerging from the ER and causing ER stress. In response to this ER stress, multiple 
proteins are activated as a part of stress-responsive pathways, some of are shared with 
interferon-regulated pathways. For example, the ER stress mediator RNA dependent 
protein kinase-like ER kinase (PERK), an ER-resident membrane protein, is directly 
activated during viral infection (3). Overall, the ER acts as a platform to support infection-
induced change in proteome distribution and proteins translocation between ER to 
different organelles e.g. mitochondrial-associated ER membrane (MAM) (4).  
Viperin is one such ER-associated protein that has been shown to be up-regulated during 
viral infection and translocate from the ER to mitochondria, specifically during
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 human cytomegalovirus pathogenesis (5,6). Viperin has been identified to participate in 
a diverse range of antiviral functions, including modulating immune signalling, metabolic 
and secretory pathways (7-16). The seemingly broad spectrum functions attributed to 
viperin appear to be dependent on the identity of the infecting viruses, as it is observed 
to interact with different protein targets dependent upon the virus.  However, we 
hypothesized that there is a unifying mechanism that may explain viperin's aooarantly 
diverse modes of action. In our study, we have investigated viperin's interaction with 
various host and viral proteins, involved in multiple metabolic and signaling pathways. 
Viperin was shown to directly interact with the innate immune signaling proteins IRAK1 
and TRAF6, and stimulate the K-63 linked ubiquitination of IRAK1 by the ubiquitin ligase 
TRAF6 (Chapter 4) (17). It was also shown to interact with the viral protein NS5A and 
target it for degradation through proteasome-mediated degradation, especially in the 
presence of the sterol-binding protein, VAP-33 (Chapter 3). Although no direct interaction 
between viperin and the cholesterol biosynthesis protein farnesyl pyrophosphate 
synthase (FPPS) to be established, it seemed that the intracellular level of FPPS is down-
regulated by viperin, probably through proteosomal or lysosomal degradation pathway 
(Chapter 2) (18). This observation indicates that viperin may interact with other proteins 
and indirectly regulate FPPS. 
Previous studies have shown that overexpression of viperin in BSR cells reduced the 
cholesterol and sphingomyelin levels in cell membranes (19). Label-free mass 
spectrometric study on the ATDC5 cultures overexpressing viperin showed differential 
expression of C-X-C motif chemokine 10 (CXCL10), a pro-inflammatory cytokine involved 
in chemotaxis, differentiation, and activation of peripheral immune cells (20). Using similar 
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mass spectrometric studies, viperin was found to interact with and inhibit the function of 
the cellular secretory protein Golgi brefeldin A-resistant guanine nucleotide exchange 
factor 1 (GBF1) (16). Cumulatively, the results from previous studies by other laboratories 
together with our present investigations suggest that viperin may associate with one or 
multiple cellular pathways involved in the viral replication process. 
A comprehensive identification and understanding of the protein-protein interaction 
network of viperin can be obtained through mass spectrometry-based proteomics 
analysis (21). This is a quantitative approach to identify the alteration in protein 
abundances and post-translational modifications in various cellular processes, including 
viral infection and activation of the innate immune system (4,22). To this end, a 
proteomics study of viperin’s interaction partners was undertaken, using co-
immunoprecipitation of viperin, followed by mass spectrometric analysis. Collaborating 
with the University of Michigan bioinformatics and proteomics core, and Prof. Alexey 
Nesvizhskii’s laboratory in the Department of Pathology, University of Michigan, we tried 
to determine the “interactome” of viperin through proteomic analysis with the objective of 
detecting unknown cellular interaction partners of viperin and the pathways they are 
involved in. This study may also highlight the common features of its target proteins.  
We identified multiple cholesterol biosynthesis proteins, as the most enriched hits in 
the interactome of viperin. These proteins are mostly involved in the formation of 
lanosterol from farnesylpyrophosphate [Figure 5.1], suggesting that this is the major 
cellular pathway that viperin modulates. This observation also explains viperin's ability to 
block the viral budding process of several enveloped viruses by reducing cellular 
cholesterol levels. This study also identifies a few ubiquitin-conjugating proteins, 
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indicating that viperin may also be a part of the ubiquitin-dependent degradation pathway, 
through which it promotes the degradation of its target proteins (e.g. NS5A, FPPS). Taken 
together, our study explored several unique targets of viperin. 
 
Figure 5.1: A schematic diagram, showing different steps in cholesterol 
biosynthesis. Steps catalysed by various cholesterol biosynthetic enzymes, observed 
to be interacting with viperin, as detected in affinity purified mass spectrometry (see 




5.2 Results In order to identify the proteins interacting with viperin, we performed 
immunoprecipitation of viperin, overexpressed in HEK293T cells, followed by tryptic 
digestion and mass spectrometric analysis of the immunoprecipitated samples. To obtain 
a consistent expression level of viperin, a Tet-on HEK293T cell-line, stably expressing 
viperin under the control of a tetracycline inducible promoter was generated as described 
in Appendix A.5.  This cell line was used for initial screening of the interaction partners 
of viperin. However, transient transfection of viperin in HEK293T cells allowed us to 
achieve higher peptide counts compared to stably expressing viperin in tetracycline-
induced cells. Therefore, the final interactome study was conducted using transiently 
transfected viperin in HEK293T cells.  
5.2.1 Immunoprecipitation of viperin using epitope tagged beads and MS analysis 
on the immunoprecipitated protein complex. A 3x-FLAG-tagged construct of viperin 
in pcDNA3.1(+), was transfected into HEK293T cells, and expressed for 42 hours post 
transfection. This protein was immunoprecipitated using anti-FLAG magnetic beads. An 
empty 3x-FLAG tagged pcDNA3.1(+) construct was transfected in HEK293T cells as the 
empty vector control (Refer to the experimental procedure section for details). To recover 
immunoprecipitated proteins from the beads, on-bead tryptic-digestion was performed by 
the University of Michigan proteomics core using sequential reduction, alkylation and 
trypsin digestion of the proteins. Mass spectrometry of the peptides was performed using 
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher). The dataset was 
analysed by Proteome Discoverer™ (v2.1Thermo Fisher) and queried against UniProt 
Homo Sapiens database. The MS analysis was performed on three biological replicates 
for both viperin and control samples.  
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5.2.2 Screening of the protein dataset and pathway analysis. The initial protein list, 
containing over 4000 hits [Appendix A.4], was screened by setting the cut off for the 
fold change of the peptide-to-spectrum matches (PSMs) of viperin samples over the 
controls as ≥3. The shortened list was then screened through the Contaminant 
Repository for Affinity Purification (CRAPome) database to exclude the non-specific 
background proteins (i.e contaminants). A confidence score was assigned to the 
remaining proteins in the list by Significance Analysis of INTeractome (SAINT) software, 
which was used to predict the probability of a true interaction between a particular protein 
hit and viperin. By setting the SAINT probability cut off as >0.9, we obtained a list of 100 
possible hits. We next performed a pathway enrichment analysis on these hits using 
DAVID, v6.8 (The Database for Annotation, Visualization and Integrated Discovery) 
software. Functional annotation of these proteins through KEGG pathway analysis 
showed the highest enrichment scores for cholesterol and sterol biosynthesis 
processes, suggesting that the cholesterol biosynthesis proteins are the top hits in the 
interactome of viperin (Enrichment score 3.59 in DAVID at high stringency). The 
following cholesterol biosynthesis enzymes were observed in the proteomics analysis, 




Protein Gene Name Fold Change Function 
Lanosterol synthase LSS 33.4 Epoxysqualene to lanosterin 






NSDHL 15.2 Lanosterol  to  Zymosterol 
Lanosterol 14-alpha 
demethylase CYP51A1 10.3 C-14 demethylation of lanosterol 
3-keto-steroid reductase HSD17B7 10 reduction of the keto group on the C-3 of sterols 
Squalene synthase FDFT1 5.5 FPP to Squalene synthesis 
 
Table 5.1: List of cholesterol biosynthesis proteins enriched in the bait-protein complex, 
co-immunoprecipitated with viperin at endogenous level.  
 
Besides cholesterol biosynthesis proteins, we also observed iron-sulfur cluster installing 
proteins and E3-Ubiquitin ligase associated proteins in the top 100 proteins hits, though 
they were not the most enriched pathways in DAVID analysis.  The following proteins 
were observed: 
Iron-Sulfur cluster installing proteins: 
Protein Name Gene name Fold Change Function 
Probable cytosolic iron-
sulfur protein assembly 
protein CIAO1 (WD repeat-
containing protein 39) 
CIAO1 
 
5.75 Facilitates the assembly of most 
cytosolic-nuclear Fe/S proteins 
MMS19 nucleotide 




Acts as an adapter between 
different protein components in 
cytosolic Fe-S cluster assembly 
complex 
 
Table 5.2: List of iron-sulfur cluster installing proteins observed in the bait-protein 
complex, co-immunoprecipitated with viperin at endogenous level. 
 
E3 Ubiquitin ligase/ Ubiquitin associated proteins: 
Protein Gene name Fold Change Function 
UBX domain-containing 








dissociated protein 2 CAND2 5.1 
Assembly factor of SCF 
(SKP1-CUL1-F-box protein) 
E3 ubiquitin ligase complexes 
that promotes the exchange 
of the substrate-recognition 
F-box subunit in SCF 
complexes 
 
Table 5.3: List of ubiquitin ligase or ubiquitin associated proteins observed in the bait-
protein complex, co-immunoprecipitated with viperin at endogenous level. 
 
Several sphingolipid biosynthesis and metabolic proteins were also observed, although 
with a lower enrichment score in pathway analysis. Viperin was shown to regulate 
intracellular level of sphingomyelin (19), therefore it may be possible that by regulating 
these proteins viperin is modulating the levels of cellular sphingolipids.  







sphingoid bases (PSBs), such 
as sphingosine-1-phosphate, 
into fatty aldehydes and 
phosphoethanolamine 
serine palmitoyltransferase 





9.6 and 13.7 
respectively 
Formation of 3-oxasphinganine 
from hexadecanoyl-CoA 
Aldehyde dehydrogenase 3 
family member A2 
ALDH3A2 
 3.8 
Conversion of the sphingosine 
1-phosphate (S1P) 
degradation product 
hexadecenal to hexadecenoic 
acid 
 
Table 5.4: List of sphingolipid metabolic proteins observed in the bait-protein complex, 
co-immunoprecipitated with viperin at endogenous level. 
 
5.3 Discussion Viperin seems to be involved in various cellualr pathways (e.g. the innate 
immune signaling pathway and lipid biosynthesis); however very few studies have been 
focused on obtaining a comprehensive list of proteins belonging to the interactome of 
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viperin. To date, most investigations of viperin’s antiviral effects have used cell-culture 
based experiments in which the antiviral activity of the enzyme was assayed either by 
measuring decreases in viral titer or viral RNA levels. Consequently, it seems that the 
mechanism by which viperin exerts its anti-viral activity differs in different viral strains. 
However, viperin’s ability to target a broad range of viruses implies a unifying underlying 
mechanism, possibly by regulating a few specific biochemical pathways important to viral 
infection. Therefore, we focused on biochemical and proteomics approaches to identify 
the proteins that viperin interacts with at endogenous level.  
In this study, we identified several cholesterol biosynthesis proteins as interacting with 
viperin at endogenous levels of expression. The two most enriched proteins in the viperin 
interactome are lanosterol synthase (LSS) and squalene monooxygenase (SQLE), 
involved in the formation of lanosterol from squalene (23). As the sterol biosynthetic 
proteins interact with each-other in a functional complex, it is possible that most of the 
proteins are being enriched through indirect interactions, rather than binding directly to 
viperin. Notably, the cholesterol biosynthetic enzymes detected in this study are ER-
resident proteins and probably their subcellular localization is important for the interaction 
with viperin. Interestingly, consistent with the results obtained previously (Chapter 2), 
viperin was not observed to directly interact with the cytosolic protein 
farnesylpyrophospahte synthase (FPPS) at endogenous level.  
Previous studies have demonstrated that lanosterol synthase (LSS) and squalene 
synthase (FDFT1) are essential for viral replication and potential targets for antiviral 
drugs. Inhibition of LSS and FDFT1 with small molecule inhibitors reduced the infection 
of Human rhino virus and hepatitis C virus, respectively and modulated the innate immune 
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system (24),(25). Therefore, by interacting with these proteins, viperin may retard or stall 
the cholesterol biosynthesis and thereby, inhibit the viral budding process.   
In addition to regulating cholesterol, viperin may also exert its anti-viral activity by 
interacting with and inhibiting the sphingolipid biosynthesis associated proteins, identified 
in the analysis. Sphingolipids and their metabolites are potential key regulators in viral 
replication, assembly and release of several viruses, e.g. HIV (26). Prevention of in vivo 
sphingolipid synthesis by serine palmitoyltransferase disrupted the infection of HCV in 
human hepatocytes (27), suggesting that viperin may use similar mechanism to exhibit 
viral regulation by inhibiting serine palmitoyltransferase.      
The presence of ubiquitin-conjugating enzymes (E3 ubiquitin ligases) in the viperin bait-
protein complex strengthened the idea the fact that viperin is involved in ubiquitin-
mediated signaling pathways and degradation pathways. We did not find any specific 
K63-linked ubiquitin ligase in the analysis. However, intriguingly, the occurrence of 
ubiquitin-dependent endoplasmic reticulum-associated degradation (ERAD) proteins in 
the interactome support our observation that viperin promotes the degradation of its target 
proteins (e.g. FPPS and NS5A) through the proteosomal degradation pathway (refer to 
chapter 2 and 3). In fact, several of the cholesterol biosynthetic enzymes, present in the 
immunoprecipitated protein complex, are also known to be controlled through 
proteosomal degradation (28).  
The identification of the key enzymes involved in cholesterol synthesis as the interaction 
partners of viperin provides new insights into viperin’s anti-viral activity. Our observations 
provide evidence to support viperin’s ability to regulate cholesterol and lipid metabolism 
and stall the viral budding process for enveloped viruses.  Further biochemical studies 
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will be needed to validate the interaction of the individual proteins identified in this analysis 
with vipeirn. This will then set the stage to identify common structural and functional motifs 
that viperin recognizes and binds to. 
 
5. 4 Experimental Procedure 
Cell line HEK293T cells were obtained from ATCC. 
Reagents Transfection agent Fugene HD was purchased from Promega (E2311). Anti-
FLAG® M2 Magnetic Beads, bound with anti-FLAG mouse monoclonal antibody, was 
purchased from Sigma-Aldrich (M8823). Reagents for on-bead tryptic digestion of viperin 
peptides were provided by the proteomics core, Department of pathology, University of 
Michigan. Anti-viperin rabbit polyclonal and mouse monoclonal antibodies are purchased 
from ProteinTech and EMD Millipore, respectively.  
Cloning and Expression of viperin in HEK293T cells Full length 3x-FLAG tagged 
viperin in pcDNA3.1(+)  was cloned as described in the experimental section of Chapter 
2. The 3x-FLAG tagged pcDNA3.1(+), used as an empty vector control, was a kind gift 
from Dr. Brent Martin Lab, Department of Chemistry, University of Michigan. Expression 
of viperin or empty vector construct was achieved through transient transfection method 
in HEK293T cells (cultivated in DMEM supplemented with 10% FBS and 1% antibiotics). Briefly, 
17 µg of the respective plasmid DNA construct was mixed with FuGENE HD reagent in a 3:1 ratio, 
incubated at room temperature for 15 min, and then added to HEK293T cells at 40% confluence 
on a 100-mm dish. The transfected cells were then grown for up to 48 h, gently pelleted, and 
stored at –80 °C until use. 
109 
 
Immunoprecipitation of viperin with anti-FLAG magnetic beads HEK293T cells over-
expressing 3x-FLAG-viperin or 3x-FLAG-tagged empty vectors (3x-FLAG-pcDNA3.1) as 
a control were harvested in PBS from 100 mm plates. Each biological replicate was 
pooled from 3x 100 mm plates to maximize the protein concentration in the lysate. The 
cells were lysed one ice with lysis buffer (Tris-buffer saline with 0.1% Tween 20, 10% 
glycerol and protease inhibitors) and centrifuged for 20 minutes at 14,000 RPM at 4˚C. 
Total protein concentration of the supernatant was measured by Protein DC Assay (Bio-
Rad) and subjected to immunoprecipitation using Anti-Flag M2 magnetic beads (Sigma-
Aldrich). Supernatant with total protein concentration ~ 7ug/ul was incubated with the anti-
FLAG magnetic beads (pre-equilibrated with lysis buffer) at 50:1 (w/v) ratio for two hours 
at room temperature. Beads were washed thrice with 20x bead volume of TBS and 
submitted to bioinformatics and proteomics core, Department of Pathology, University of 
Michigan. The efficiency of immunoprecipitation was determined through SDS gel 
electrophoresis, followed by Coomasie blue staining and immunoblotting technique 




Figure 5.2: Determination of immunoprecipitated viperin using anti-FLAG tagged magnetic beads 
by (A) coomasie staining of the samples, analysed by SDS PAGE and (B) immunoblotting with 
anti-viperin antibody. The abbreviation used in the image are crude extract (C.E); flow-through 
(F.T); first, second and third wash (W1, 2, 3 respectively); first and second elution (E1 and 2 
respectively).  
 
In solution digestion and Mass spectrometric analysis At the proteomics core, the 
beads were re-suspended in 50 µl of 0.1M ammonium bicarbonate buffer (pH~8).  
Cysteines were reduced by adding 50 µl of 10 mM DTT and incubating at 45° C for 30 
min.  Samples were cooled to room temperature and alkylation of cysteines was achieved 
by incubating with 65 mM 2-Chloroacetamide, under darkness, for 30 min at room 
temperature.  An overnight digestion with 1 ug sequencing grade, modified trypsin was 
carried out at 37° C with constant shaking in a Thermomixer.  Digestion was stopped by 
acidification and peptides were desalted using SepPak C18 cartridges using 
manufacturer’s protocol (Waters).  Samples were completely dried using vacufuge.  
Resulting peptides were dissolved in 8 µl of 0.1% formic acid/2% acetonitrile solution and 
2 µls of the peptide solution were resolved on a nano-capillary reverse phase column 
(Acclaim PepMap C18, 2 micron, 50 cm, ThermoScientific) using a 0.1% formic acid/2% 
acetonitrile (Buffer A) and 0.1% formic acid/95% acetonitrile (Buffer B) gradient at 300 
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nl/min over a period of 180 min (2-22% buffer B in 110 min, 22-40% in 25 min, 40-90% in 
5 min followed by holding at 90% buffer B for 5 min and re-quilibration with Buffer A for 
25 min).  Eluent was directly introduced into Orbitrap Fusion tribrid mass spectrometer 
(Thermo Scientific, San Jose CA) using an EasySpray source.  MS1 scans were acquired 
at 120K resolution (AGC target=1x106; max IT=50 ms).  Data-dependent collision induced 
dissociation MS/MS spectra were acquired using Top speed method (3 seconds) 
following each MS1 scan (NCE ~32%; AGC target 1x105; max IT 45 ms).   
Proteins were identified by searching the MS/MS data against Homo sapiens protein 
database (UniProt; 42054 entries, 2016-11-30) using Proteome Discoverer (v2.1, Thermo 
Scientific).  Search parameters included MS1 mass tolerance of 10 ppm and fragment 
tolerance of 0.2 Da; two missed cleavages were allowed; carbamidimethylation of 
cysteine was considered fixed modification and oxidation of methionine, deamidation of 
aspergine and glutamine, phosphorylation of serine, threonine and tyrosine, ubiquitination 
of lysine (diglycine signature) were considered as potential modifications.  False 
discovery rate (FDR) was determined using Percolator and proteins/peptides with a FDR 
of ≤1% were retained for further analysis.   
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 Significance of the Study in Probing Viperin’s Anti-viral activity 
and Future Outlooks 
 
A better understanding of viral infection presents major opportunities for the improvement 
of public health and further mechanistic studies are required for the development of 
antiviral therapeutics. The development of anti-viral drugs lags behind anti-bacterial 
drugs; therefore, a better understanding of the mechanism of action of natural antiviral 
agents could lead to the design of new antiviral therapeutics. 
By exploring the mechanism of action of viperin we aim to establish a better 
understanding of the mechanisms by which eukaryotic cells inhibit viruses. To date, most 
studies have employed cell culture-based experiments in which the antiviral activity of the 
enzyme was assayed either by measuring decreases in viral titer or viral RNA levels. 
Consequently, it seems that the mechanism of viperin’s antiviral activity differs in different 
viral strains. However, viperin’s ability to target a broad range of viruses implies a unifying 
underlying mechanism. Therefore, I focused on enzymatic and biochemical approaches 
to address the mechanism of viperin’s antiviral action at the molecular level. The 
involvement of radical SAM chemistry in the mammalian antiviral responsive system was 
unexpected and sets viperin apart from other radical SAM enzymes. My dissertation 
project is unique in residing at the interface of immunology and enzymology and aims to 
break new ground in our understanding of the innate immune system. 
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With the recent finding that viperin’s enzymatic reaction involves the radical-mediated 
dehydration of CTP, the goal of my project was to find out how viperin regulates its target 
proteins and the relationship of this regulatory function, if any to its enzymatic activity. 
Here, collaborating with other Marsh laboratory members and Prof. Robert Kennedy’s 
laboratory at the Department of Chemistry, University of Michigan, I have shown that 
viperin regulates cellular and viral proteins in vivo, clearly indicating that it may have a 
role in controlling metabolic and signaling pathways, along with producing antiviral 
ribonucleotides (ddhCTP). However, further studies must be pursued to achieve a 
complete insight into the mechanism of viperin in regulating various cellular pathways.  
6.1 Regulation of intracellular expression of FPPS by Viperin: Following the work of 
Wang et al (2), the regulation of FPPS by viperin (3) was the starting point for our research 
on viperin. We demonstrated that over-expression of viperin in human embryonic kidney 
cells (HEK293T), reduces the intracellular accumulation of FPPS, but does not inhibit or 
inactivate FPPS. These results suggested that the reduction in activity of FPPS in cell 
lysates, as shown by Wang et al, is due to increased degradation of FPPS by viperin, and 
not because of a direct interaction between these two proteins. Mutagenesis studies on 
the radical SAM domain and reductive SAM cleaving activity of viperin implied that viperin 
in this case may not act as a radical SAM enzyme in regulating FPPS.  However, the 
enzymatic activity of viperin was only measured based on the 5’-deoxyadenosine 
produced from the uncoupled reaction of SAM, as CTP was known to be the co-substrate 
of viperin at the time. Therefore, in the light of new information regarding the catalytic 
activity of viperin, it would be profitably to re-explore whether FPPS acts as a regulator of 
viperin’s activity in producing the antiviral nucleotide ddhCTP.  
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As the localization of viperin to the endoplasmic reticulum was crucial for its inhibitory 
activity against FPPS, it seems that FPPS might be localized to a membrane structure in 
the presence of viperin. Therefore, it would be interesting investigate the cellular 
localization of FPPS changes when co-expressed with viperin.  Moreover, the in vivo 
degradation of FPPS by viperin, as suggested by our studies, could be investigated in 
more detail in light of the results obtained from our proteomics study that found that viperin 
interactd with several ERAD-associated ubiquitin ligases. 
6.2 Inactivation of viperin’s enzymatic activity to produce 5’-deoxyadenosine 
through the interaction with viral protein NS5A and VAP-33. Although the 
involvement of radical chemistry in the regulation of FPPS by viperin was ruled out, it is 
still possible that radical SAM chemistry plays a role in viperin’s regulation of other protein 
targets. The viral protein NS5A, a potential protein target of viperin (4,5), is known for its 
importance in regulating viral replication of hepatitis C virus (HCV) (6-9). As viperin was 
shown to limit viral replication by producing the antiviral nucleotide ddhCTP, we undertook 
experiments to investigate how viperin’s catalytic activity is altered when interacting with 
NS5A. We showed that the interaction between viperin and NS5A in the presence of an 
adaptor protein VAP33 leads to the degradation of NS5A through proteosomal 
degradation pathway. However, interestingly, co-expression of NS5A and VAP-33 with 
viperin reduced the enzyme’s activity, suggesting that NS5A may have evolved to bind 
viperin as a strategy to reduce ddhCTP synthesis and thereby reduce the possibility of 




These results pose new questions regarding whether viperin regulates the interaction of 
NS5A with viral polymerase NS5B within the HCV replication complex to control the viral 
replication process. Re-constitution of the protein-complex between viperin, NS5A and 
other components in the replication complex in vivo may reveal insights of the regulatory 
features of viperin on NS5A.  
Because the membrane localization of viperin, NS5A and VAP-33 is important for the 
interaction of these proteins and the inhibition of viperin’s activity, the expression and 
purification of these proteins using a nanodisc system would greatly facilitate their study. 
Formation of the nanodiscs of viperin can be achieved by slowly removing detergent from 
the solution while incubating cell lysate expressing viperin with membrane scaffolding 
proteins and phospholipids. This method can be applied to cell lysate co-expressing 
viperin with its interacting proteins, especially membrane bound protein partners NS5A 
and VAP-33, enabling the formation of the protein complex within the nanodiscs. In this 
way, the biologically significant complex between viperin, NS5A and VAP-33 could be 
isolated in vitro and the enzymatic activity of viperin investigated. 
6.3 Activation of viperin’s activity by Toll-like receptor signaling proteins IRAK1 
and TRAF6. Following the work of Saitoh et al (10), we investigated how viperin’s 
enzymatic activity is regulated by the innate immune signaling protein partners, IRAK1 
and TRAF6. Reconstituting the interactions between viperin, IRAK1 and TRAF6 by 
transiently expressing these enzymes in HEK 293T cells, we showed that IRAK1 and 
TRAF6 increase viperin activity by ~10-fold to efficiently catalyze the radical-mediated 
dehydration of CTP to ddhCTP. Furthermore, we found that TRAF6-mediated 
ubiquitination of IRAK1 requires the association of viperin with both IRAK1 and TRAF6. 
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However, to exclude the possibilities that the change in viperin’s activity by IRAK1 and 
TRFA6 is not aided by other proteins in HEK293T cells, further studies with purified 
enzymes will be needed to validate this mechanistic proposal. The modification of 
ubiquitination level of IRAK1 by TRFA6 in the presence of viperin may be also 
investigated further with the purified proteins. As IRAK1 and TRAF6 are known interaction 
partners of viperin, structural studies on viperin with CTP, in the presence of these purified 
signaling proteins may reveal the binding site conformation of the biologically significant 
protein-small molecule complex.  
6.4 Interactome analysis of viperin and identification of cholesterol biosynthesis 
proteins. It is clear from the results from Chapter 2 that viperin does not directly interact 
with or inactivate FPPS. We hypothesize that viperin may recruit additional proteins in 
degrading FPPS. To this end, the pathway analysis of viperin and obtaining a complete 
inventory of interacting protein partners through proteomics methods assumes new 
importance. This was achieved by the proteomics study on the immunoprecipitated 
viperin. 
The initial proteomic analysis of viperin interaction partners indicates that it interacts with 
various proteins involved in cholesterol and lipid biosynthesis and in regulatory pathways. 
Enrichment of cholesterol biosynthesis proteins in the interactome indicated that viperin 
might exert its antiviral activity by controlling cellular cholesterol levels and thereby retardi 
the viral assembly and budding process. Various ubiquitin-conjugating enzymes were 
also found in the “interactome” of viperin, strengthening the idea that viperin is involved 
in ubiquitin-mediated signaling or degradation pathway. 
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The interaction between viperin and the cholesterol biosynthesis enzymes may be further 
validated by co-expressing these proteins with viperin in vivo and monitoring how viperin 
alters their cellular expression and localization. For example, the two most highly enriched 
cholesterol biosynthetic enzymes, lanosterol synthase and squalene monooxygenase 
may be considered as two potential targets of viperin. It would be valuable to see if viperin 
reduces the enzymatic activity of these enzymes in catalyzing various steps in the 
cholesterol synthesis. Changes in the activity of these enzymes as a result of their 
interaction with viperin might also be investigated in a cell free environment using purified 
enzymes. Simultaneously, the changes to the catalytic activity of viperin while bound to 
the cholesterol biosynthetic enzymes, can be also explored.  
Apart from the functional annotation of the proteins observed in the interactome of viperin, 
a further extensive analysis of the sequence and the structure of the proteins may reveal 
a common structural motif that viperin binds to or common post-translational modification 
performed by viperin on its protein targets. This may provide important structural insights 
of the binding site of viperin while forming complex with the interacting. 
Considering previous studies by other groups and the results obtained in our studies on 
viperin, it seems viperin exerts its antiviral activity in two ways. Firstly, viperin likely directly 
inhibits the viral genomic replication by producing antiviral nucleotide ddhCTP. 
Additionally, viperin acts as a regulatory protein in cellular pathways involved in viral 
pathogenesis, by interacting with cellular or viral proteins. However, our study also 
suggested that these two functions are inter-related and equally contribute towards 
potentiating viperin’s antiviral activity.  
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The interplay between these two functions of viperin may be explored further by 
investigating the biological effects of antiviral nucleotide ddhCTP more broadly. It might 
be possible that viperin modifies ddhCTP further to an epoxy-containing nucleotide which 
may act as an antiviral nucleotide analog against a broader range of viruses beyond 
flaviviruses [Figure 6.1]. Alternatively, viperin could also employ this epoxy-nucleotide to 
covalently modify nucleophilic protein sidechains through Michael addition to the 
electrophilic epoxide. To this end, identification, characterization and isolation of the 
modified nucleotide (ddhCTP or the epoxy-analog of ddhCTP) is required.   
 
Figure 6.1: Schematic diagram of conversion of ddhCTP to epoxy-ddhCTP and Michael 
addition of nucleophilic side chain residues of protein 
 
Native mass spectrometry could be used to identify the complex formed between viperin 
and its product.  Furthermore, the kinetics of ddhCTP formation (or its analogs) catalyzed 
by viperin in the presence of its interacting proteins would be informative to investigate. 
Such studies are essential to understand the regulation of viperin by its interacting 
proteins. Ultimately, structural studies on viperin with the modified nucleotides, co-
crystalized with its interacting protein partner, may provide insights of the binding 
conformation of protein-protein and enzyme-substrate or enzyme-product complex.  
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Taking these approaches, we may advance the prospect of establishing a unifying 
mechanism underlying the role of viperin in regulating the antiviral response. 
Furthermore, this may lead to developing the antiviral therapeutics, mimicking the 




1. Gizzi, A. S., Grove, T. L., Arnold, J. J., Jose, J., Jangra, R. K., Garforth, S. J., Du, 
Q., Cahill, S. M., Dulyaninova, N. G., Love, J. D., Chandran, K., Bresnick, A. R., 
Cameron, C. E., and Almo, S. C. (2018) A naturally occurring antiviral 
ribonucleotide encoded by the human genome. Nature 558, 610-614 
2. Wang, X., Hinson, E. R., and Cresswell, P. (2007) The Interferon-Inducible Protein 
Viperin Inhibits Influenza Virus Release by Perturbing Lipid Rafts. Cell Host 
Microbe 2, 96-105 
3. Makins, C., Ghosh, S., Román-Meléndez, G. D., Malec, P. A., Kennedy, R. T., and 
Marsh, E. N. G. (2016) Does Viperin Function as a Radical S-Adenosyl-l-
methionine-dependent Enzyme in Regulating Farnesylpyrophosphate Synthase 
Expression and Activity? J. Biol. Chem. 291, 26806-26815 
4. Helbig, K. J., Eyre, N. S., Yip, E., Narayana, S., Li, K., Fiches, G., McCartney, E. 
M., Jangra, R. K., Lemon, S. M., and Beard, M. R. (2011) The antiviral protein 
viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 
5A. Hepatology 54, 1506-1517 
5. Wang, S., Wu, X., Pan, T., Song, W., Wang, Y., Zhang, F., and Yuan, Z. (2012) 
Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to 
host protein hVAP-33. J. Gen. Virol. 93, 83-92 
6. Foster, T. L., Belyaeva, T., Stonehouse, N. J., Pearson, A. R., and Harris, M. 
(2010) All three domains of the hepatitis C virus nonstructural NS5A protein 
contribute to RNA binding. J. Virol. 84, 9267-9277 
7. Reyes, G. R. (2002) The nonstructural NS5A protein of hepatitis C virus: An 
expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J. 
Biomed. Sci. 9, 187-197 
8. Shimakami, T., Hijikata, M., Luo, H., Ma, Y. Y., Kaneko, S., Shimotohno, K., and 
Murakami, S. (2004) Effect of Interaction between Hepatitis C Virus NS5A and 
NS5B on Hepatitis C Virus RNA Replication with the Hepatitis C Virus Replicon. J. 
Virol. 78, 2738-2748 
123 
 
9. Shirota, Y., Luo, H., Qin, W., Kaneko, S., Yamashita, T., Kobayashi, K., and 
Murakami, S. (2002) Hepatitis C Virus (HCV) NS5A Binds RNA-dependent RNA 
Polymerase (RdRP) NS5B and Modulates RNA-dependent RNA Polymerase 
Activity. J. Biol. Chem. 277, 11149-11155 
10. Saitoh, T., Satoh, T., Yamamoto, N., Uematsu, S., Takeuchi, O., Kawai, T., and 
Akira, S. (2011) Antiviral Protein Viperin Promotes Toll-like Receptor 7- and Toll-
like Receptor 9-Mediated Type I Interferon Production in Plasmacytoid Dendritic 






















Appendix A1: Gene sequences of proteins used in this study 
 













































































































































































































Appendix A2: Generation of standard curve to measure the amount of 
viperin present in the HEK293T cell lysate for reductive SAM assay 
 
 
Appendix A2:  
Figure A2 (Left) Flowchart illustrating the procedure used to determine the amount of 
viperin in HEK 293T lysates. (Right) Representative standard curve constructed from 
increasing concentrations of purified ΔN-viperin, visualize by immunoblotting and 
quantified. The standard curve was used to estimate the concentration of viperin in HEK 













Appendix A3: Calculation of turnover number of viperin and viperin-
ΔN50 in the presence of NS5A and VAP-33 
 
 
Appendix A3: Co-expression of NS5A and VAP-33C inhibits reductive SAM cleavage 
activity of Viperin in HEK293T cell-lysates.  
Figure A3 (A) Immunoblotting of vipeirn, NS5A and VAP-33C present in the samples. (B) 
Immunoblotting of viperinΔN50, in the presence of NS5A and VAP-33C in HEK293T cells. 
Table A3 (A) The relative activity was of viperin was determined by the ratio of 5’-
deoxyadenosine produced to amount of viperin present in the sample per hour. (B) 
Calculation of specific activity of viperinΔN50, determined by the ratio of 5’-
deoxyadenosine produced to amount of viperin present in the sample per hour.  
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Appendix A4: Calculation of turnover number of viperin in the 
presence of TRAF6 and IRAK1 
 
 5’dA (pmol) Viperin (pmol) Turnover (h-1) 
Viperin 1.30 ± 0.01 1.38 ± 0.07 
 
 
0.94 ± 0.04 
Viperin +TRAF6 1.27 ± 0.01 1.10 ± 0.06 
 
1.15 ± 0.06 
 
Viperin + IRAK1 1.49 ± 0.02 
 
0.70 ± 0.04 
 




1.72 ± 0.03 
 
0.40 ± 0.02 
 
4.30 ± 0.22 
 
Viperin +CTP 3.10 ± 0.15 
 
1.38 ± 0.07 2.25 ± 0.16 
Viperin + 
IRAK1+CTP 
5.09 ± 0.17 0.70 ± 0.04 
 
7.27 ± 0.48 
Viperin +IRAK1+ 
TRAF6+CTP 
8.55 ± 0.48 0.40 ± 0.02 
 
21.4 ± 1.6 
 
 
Table A4: Calculation of specific activity of viperin in the presence of TRAF6 and IRAK1. 
The relative activity was of viperin was determined by the ratio of 5’-deoxyadenosine 
produced to amount of viperin present in the sample per hour. 
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Appendix A5: List of proteins as potential candidates for the 
interactome of viperin 
 








Q8WXG1 RSAD2 Radical S-adenosyl methionine 
domain-containing protein 2 
[OS=Homo sapiens] 
388 431 455 
 
P48449 LSS lanosterol synthase [OS=Homo 
sapiens] 
53 27.5 29.5 1 
Q14534 SQLE squalene monooxygenase 
[OS=Homo sapiens] 
18.5 18.5 52 1 
Q6ZRQ5 MMS22L Protein MMS22-like [OS=Homo 
sapiens] 
22 24 28 1 
Q6NUQ4 TMEM214 Transmembrane protein 214 
[OS=Homo sapiens] 
31 17.5 28 1 
Q9UHG3 PCYOX1 prenylcysteine oxidase 1 
[OS=Homo sapiens] 
19 23 28 1 
O95470 SGPL1 sphingosine-1-phosphate lyase 1 
[OS=Homo sapiens] 
19 24 22 1 
P07099 EPHX1 epoxide hydrolase 1 [OS=Homo 
sapiens] 
18 19 24 1 
O94830 DDHD2 Phospholipase DDHD2 [OS=Homo 
sapiens] 
14.5 33 19 1 
Q9H497 TOR3A Torsin-3A [OS=Homo sapiens] 17.5 17.5 21 1 
Q9H6V9 LDAH Isoform 2 of Lipid droplet-
associated hydrolase [OS=Homo 
sapiens] 
20 14 24 1 
Q96AD5 PNPLA2 Patatin-like phospholipase domain-
containing protein 2 [OS=Homo 
sapiens] 
16 17 15 1 
P23786 CPT2 Carnitine O-palmitoyltransferase 2, 
mitochondrial [OS=Homo sapiens] 
16 12.33333333 20.5 1 
Q15738 NSDHL sterol-4-alpha-carboxylate 3-
dehydrogenase, decarboxylating 
[OS=Homo sapiens] 
17 16 13.4 1 
Q9H3N1 TMX1 Thioredoxin-related transmembrane 
protein 1 [OS=Homo sapiens] 
12 14 17 1 
Q9HDC9 APMAP Adipocyte plasma membrane-
associated protein [OS=Homo 
sapiens] 
21 10.5 13.5 1 
Q96HA7 TONSL Tonsoku-like protein [OS=Homo 
sapiens] 




mitochondrial [OS=Homo sapiens] 
10 21 10 1 
O15270 SPTLC2 Serine palmitoyltransferase 2 
[OS=Homo sapiens] 
12 13 16 1 
Q32NB8 PGS1 Isoform 3 of Phosphatidate 
cytidylyltransferase, mitochondrial 
[OS=Homo sapiens] 
13 15 13 1 
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Q86UE4 MTDH protein LYRIC [OS=Homo sapiens] 20 10.2 14.66666667 1 
Q8WTS1 ABHD5 1-acylglycerol-3-phosphate O-
acyltransferase ABHD5 [OS=Homo 
sapiens] 
14 12 14 1 
Q8NBM8 PCYOX1L Prenylcysteine oxidase-like 
[OS=Homo sapiens] 
9 24 12 1 
O43156 TTI1 TELO2-interacting protein 1 
homolog [OS=Homo sapiens] 
19 8 15 1 
Q13505 MTX1 Metaxin-1 [OS=Homo sapiens] 12 13 12 1 
Q8N128 FAM177A
1 
Isoform 2 of Protein FAM177A1 
[OS=Homo sapiens] 
10 14 13 1 
O15228 GNPAT Dihydroxyacetone phosphate 
acyltransferase [OS=Homo sapiens] 
20 8.2 13.66666667 1 
Q8IZ81 ELMOD2 ELMO domain-containing protein 2 
[OS=Homo sapiens] 
12 11 12 1 
Q8NBX0 SCCPDH saccharopine dehydrogenase-like 
oxidoreductase [OS=Homo sapiens] 
9 11 12 1 
Q16850 CYP51A1 lanosterol 14-alpha demethylase 
[OS=Homo sapiens] 
9 11 11 1 
Q9UH92 MLX MAX-like protein X [OS=Homo 
sapiens] 
9 12 10 1 
P33121 ACSL1 Long-chain-fatty-acid--CoA ligase 1 
[OS=Homo sapiens] 
8.25 10.66666667 12.33333333 1 
Q9BSY9 DESI2 Desumoylating isopeptidase 2 
[OS=Homo sapiens] 
9 12 9 1 
P56937 HSD17B7 3-keto-steroid reductase [OS=Homo 
sapiens] 
8 12 10 1 
P42345 MTOR Serine/threonine-protein kinase 
mTOR [OS=Homo sapiens] 
22 6.75 10 1 
O15269 SPTLC1 serine palmitoyltransferase 1 
[OS=Homo sapiens] 
11 8 10 1 
Q9HBH5 RDH14 Retinol dehydrogenase 14 
[OS=Homo sapiens] 
8 10 11 1 
Q9BV23 ABHD6 Monoacylglycerol lipase ABHD6 
[OS=Homo sapiens] 
9 8 11 1 
Q99487 PAFAH2 Platelet-activating factor 
acetylhydrolase 2, cytoplasmic 
[OS=Homo sapiens] 
9 10 9 1 
Q96KC8 DNAJC1 DnaJ homolog subfamily C member 
1 [OS=Homo sapiens] 
9 10 9 1 
Q96E22 NUS1 Dehydrodolichyl diphosphate 
synthase complex subunit nus1 
[OS=Homo sapiens] 
8 10 9 1 
Q8TC12 RDH11 Retinol dehydrogenase 11 
[OS=Homo sapiens] 




11 [OS=Homo sapiens] 
11 6 12 1 
P50336 PPOX protoporphyrinogen oxidase 
[OS=Homo sapiens] 
9 11 7.5 1 
P21964 COMT Catechol O-methyltransferase 
[OS=Homo sapiens] 
13 16 5 1 
Q9UI26 IPO11 Isoform 2 of Importin-11 [OS=Homo 
sapiens] 
10.5 7.25 7 1 
P51648 ALDH3A2 Isoform 2 of Fatty aldehyde 
dehydrogenase [OS=Homo 
sapiens] 
12 10 3.666666667 1 
Q9NW68 BSDC1 BSD domain-containing protein 1 
[OS=Homo sapiens] 
6.5 7 7.5 1 
P40855 PEX19 Peroxisomal biogenesis factor 19 
[OS=Homo sapiens] 
4.4 11 7.2 1 
P47712 PLA2G4A Cytosolic phospholipase A2 
[OS=Homo sapiens] 
5.6 6.4 8.2 1 
O43681 ASNA1 ATPase ASNA1 [OS=Homo 
sapiens] 
5.285714286 7.166666667 6 1 
Q9BXW9 FANCD2 Isoform 1 of Fanconi anemia group 
D2 protein [OS=Homo sapiens] 
9 7.833333333 3.909090909 1 
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O60313 OPA1 Isoform 2 of Dynamin-like 120 kDa 
protein, mitochondrial [OS=Homo 
sapiens] 
6.2 5.666666667 6.090909091 1 
Q13724 MOGS Mannosyl-oligosaccharide 
glucosidase [OS=Homo sapiens] 
6.333333333 4.2 8.333333333 1 
O76071 CIAO1 Probable cytosolic iron-sulfur 
protein assembly protein Ciao1 
[OS=Homo sapiens] 
6.666666667 5.25 5.6 1 
Q9Y4R8 TELO2 telomere length regulation protein 
TEL2 homolog [OS=Homo sapiens] 
5.6 9.666666667 3 1 
Q96T76 MMS19 Isoform 5 of MMS19 nucleotide 
excision repair protein homolog 
[OS=Homo sapiens] 
5.25 4.066666667 4.857142857 1 
P40939 HADHA Trifunctional enzyme subunit alpha, 
mitochondrial [OS=Homo sapiens] 
4.090909091 3.058823529 5.454545455 1 
Q6NXR4 TTI2 TELO2-interacting protein 2 
[OS=Homo sapiens] 
6 9 12 0.99 
Q86SQ9 DHDDS Isoform 2 of Dehydrodolichyl 
diphosphate synthase complex 
subunit DHDDS [OS=Homo 
sapiens] 
7 10 9 0.99 
Q99653 CHP1 Calcineurin B homologous protein 1 
[OS=Homo sapiens] 
7 12 7 0.99 
Q92575 UBXN4 UBX domain-containing protein 4 
[OS=Homo sapiens] 
8 10 7 0.99 
P50897 PPT1 Palmitoyl-protein thioesterase 1 
[OS=Homo sapiens] 
13 5 8 0.99 
Q13190 STX5 Syntaxin-5 [OS=Homo sapiens] 9 5 8 0.99 
P00387 CYB5R3 Isoform 3 of NADH-cytochrome b5 
reductase 3 [OS=Homo sapiens] 
5 6 5.5 0.99 
O95573 ACSL3 long-chain-fatty-acid--CoA ligase 3 
[OS=Homo sapiens] 
5.333333333 4 5.5 0.99 
P55084 HADHB Trifunctional enzyme subunit beta, 
mitochondrial [OS=Homo sapiens] 
4.285714286 3.090909091 5.714285714 0.99 
Q99807 COQ7 5-demethoxyubiquinone 
hydroxylase, mitochondrial 
[OS=Homo sapiens] 
8 7 8 0.98 
Q9H1E5 TMX4 Thioredoxin-related transmembrane 
protein 4 [OS=Homo sapiens] 
6 9 8 0.98 
Q9BRX8 FAM213A Redox-regulatory protein FAM213A 
[OS=Homo sapiens] 
7 10 6 0.98 
Q6PIU2 NCEH1 Isoform 2 of Neutral cholesterol 
ester hydrolase 1 [OS=Homo 
sapiens] 
6 9 7 0.98 
Q9HAP2 MLXIP MLX-interacting protein [OS=Homo 
sapiens] 
7 6 4.5 0.98 
P43378 PTPN9 Tyrosine-protein phosphatase non-
receptor type 9 [OS=Homo sapiens] 
4.5 5 9 0.98 
O75155 CAND2 Cullin-associated NEDD8-
dissociated protein 2 [OS=Homo 
sapiens] 
4 6 5.333333333 0.98 
Q86U38 NOP9 Nucleolar protein 9 [OS=Homo 
sapiens] 
4 3.666666667 3.428571429 0.98 
Q9H1A3 METTL9 Methyltransferase-like protein 9 
[OS=Homo sapiens] 
6 9 7 0.97 
P37268 FDFT1 squalene synthase [OS=Homo 
sapiens] 
11 3.5 8 0.97 
Q9Y2Z9 COQ6 Ubiquinone biosynthesis 
monooxygenase COQ6, 
mitochondrial [OS=Homo sapiens] 
6 6 9 0.96 
Q6PI48 DARS2 Aspartate--tRNA ligase, 
mitochondrial [OS=Homo sapiens] 
3.4 4.75 4 0.96 
Q96AG4 LRRC59 Leucine-rich repeat-containing 
protein 59 [OS=Homo sapiens] 
6.333333333 2.714285714 3.833333333 0.96 
Q8WVC6 DCAKD dephospho-CoA kinase domain-
containing protein [OS=Homo 
sapiens] 
8 8 6 0.95 
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Q3SXM5 HSDL1 Inactive hydroxysteroid 
dehydrogenase-like protein 1 
[OS=Homo sapiens] 
8 6 5 0.95 
O14656 TOR1A Torsin-1A [OS=Homo sapiens] 4.5 3.666666667 6 0.95 
O75915 ARL6IP5 PRA1 family protein 3 [OS=Homo 
sapiens] 
7 5 7 0.94 
Q9Y673 ALG5 dolichyl-phosphate beta-
glucosyltransferase [OS=Homo 
sapiens] 
6 7 5 0.94 
Q6UX53 METTL7B Methyltransferase-like protein 7B 
[OS=Homo sapiens] 
6 6 5 0.94 
O75691 UTP20 Small subunit processome 
component 20 homolog [OS=Homo 
sapiens] 
8 5.666666667 3.333333333 0.94 
Q13637 RAB32 Ras-related protein Rab-32 
[OS=Homo sapiens] 
4 4 4 0.93 
A6NDU8 C5ORF51 UPF0600 protein C5orf51 
[OS=Homo sapiens] 
6 7 1.857142857 0.93 
Q99541 PLIN2 perilipin-2 [OS=Homo sapiens] 4.4 5.4 2.090909091 0.93 
P02649 APOE Apolipoprotein E [OS=Homo 
sapiens] 
9 8 4 0.92 
P53701 HCCS Cytochrome c-type heme lyase 
[OS=Homo sapiens] 
3 5 5 0.92 
P01111 NRAS GTPase NRas [OS=Homo sapiens] 3 5.5 7 0.92 
A1L0T0 ILVBL Acetolactate synthase-like protein 
[OS=Homo sapiens] 
5 5 7 0.91 
Q2TAA5 ALG11 GDP-Man:Man(3)GlcNAc(2)-PP-Dol 
alpha-1,2-mannosyltransferase 
[OS=Homo sapiens] 
4 4 5 0.91 
Q96CS3 FAF2 FAS-associated factor 2 [OS=Homo 
sapiens] 
7 4 2.6 0.91 
Q68D91 MBLAC2 Metallo-beta-lactamase domain-
containing protein 2 [OS=Homo 
sapiens] 
5 11 5 0.9 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
1 [OS=Homo sapiens] 
8 3.333333333 4.5 0.9 
P05023 ATP1A1 Sodium/potassium-transporting 
ATPase subunit alpha-1 [OS=Homo 
sapiens] 
4 6 4 0.9 
 









Appendix A6: Generation and screening of Tet-On stable cell-line, 
stably expressing viperin 
 
Cell line Tet-On 3G HEK 293T cell line was purchased from CloneTech 
Reagents pTRE3G-BI vector, linear puromycin marker,Tet-approved foetal bovine serum 
(FBS), Puromycin and Geneticin (G418) antibiotic were purchased from CloneTech.  
Doxycyclin Hyclate was purchased from Sigma. DMEM media, 0.05% Trypsin-EDTA and 
1X Phosphate buffer saline were obtained from Gibco (Thermo Fisher Scientific).  
Cloning of pTRE3G-3x FLAG viperin The viperin construct with N-terminal 3x FLAG tag 
was cloned between BamHI and NotI restriction sites in a pTRE3G-BI vector using Gibson 
Assembly method. The sequence of the construct was checked at the University of 
Michigan sequencing core.  
Creating of Tet-On 3G cell line, stably expressing 3x-FLAG-viperin Tet-On 3G cells 
were plated on a 100 mm collagen-coated plate and grown in DMEM media, 
supplemented with 10% tet-approved FBS, 1% Penicilllin/Streptamycin antibiotics and 
100 µg/ml Geneticin (G418). The cells were grown to 80% confluence (80% of the plate 
was covered by the cells) and passed in a well of a 6-well plate at 1: 4 dilution in DMEM.  
The cells were transfected with 2 µg of viperin construct, with 100 ng Puromycin selection 
marker, mixing with Fugene HD at 1:3 ratio. After 48 h post-transfection, the confluent 
cells were split into four 100-mm collagen coated plates. After 
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an additional 48 hr, the media was changed with fresh media, supplemented with 0.5 
µg/ml Puromycin. The media was replaced every four days with Puromycin supplemented 
fresh media, until the colonies were formed. About 48 large, healthy colonies were 
isolated using glass cylinders and passed into the wells in a collagen coated 24-well plate. 
The colonies were cultured in DMEM media supplemented with 10% tet-approved FBS, 
1% Penicilllin/Streptamycin antibiotics and 100 µg/ml Geneticin (G418) and 0.25 µg/ml 
Puromycin.  
Screening of colonies that are expressing 3x-FLAG-viperin The cells in each well of 
the 24-well plate were allowed to grow to 80-90% confluence and split in to 3 wells of a 
6-well collagen coated plates. The stock plate was propagated for future maintenance, 
depending on the result from the inducibility assay. The rest of the two wells were used 
for induction test. The experimental well was treated with 1000ng/ml Doxycycline Hyclate 
and the last well was treated as a negative control. 48 h post induction, the cells were 
harvested and immunoblotted to test the expression of viperin.  Six colonies, out of 48, 
showed expression of viperin upon doxycycline induction, without expression at basal 
level.  
 
Figure A6: Screening of viperin expression in Tet-On 3G cell line, stably expressing under the 
control of pTRE3G promoter
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Appendix A7: Cellular degradation pathway involved in the regulation 
of viperin expression 
 
To investigate whether a degradation pathway is involved in regulating the cellular 
expression of viperin, we performed a time-dependent accumulation of viperin in 
HEK293T cells in the presence of proteasomal and lysosomal degradation inhibitors. Both 
transiently transfected viperin in HEK293T cells and stably expressed viperin in Tet-On 
3G cells were assessed for monitoring the expression levels.  
Upon blocking the proteasomal degradation pathway with reversible, cell permeable 
inhibitor MG132, a time-dependent degradation of viperin was observed in vivo, in 
comparison to the control cells treated with DMSO. On the contrary, treatment with 
lysosomal degradation inhibitors chloroquine and ammonium chloride resulted in an 
accumulation in the cellular expression level of viperin over 16 hours post-transfection 
(for transient transfection of viperin) or post-induction (for stably expressed viperin) 
[Figure A7], indicating that the expression level of viperin is regulated through lysosomal 
degradation pathway. However, the reason behind the reduction of cellular expression 
level of viperin upon treatment with proteasome-mediated degradation inhibitor MG132 is 
not well understood. As viperin was shown to interact with several ubiquitin ligases or 
ubiquitin-interacting proteins, it could be possible that inhibition of these proteins by 




Cell  HEK293T cells were obtained from ATCC. Tet-On 3G cells stably expressing viperin 
doxycycline induction were generated as mentioned in Appendix A6.  
Materials  MG132 in DMSO solution (M7449), ammonium chloride (213330) and 
chloroquine diphosphate salt (C6628) were purchased from Sigma.  
Treatment of cells with protesome and lysosomal inhibitors  HEK293T cells and Tet 
On 3G cells were grown to 60-70% confluency and transfected with 3X-FLAG tagged 
viperin gene in pcDNA3.1 or induced with 1000ng/ml doxycycline hyclate, respectively. 
After 24 hours of transfection or induction cells were treated with MG132 in DMSO (final 
concentration 50 μM) or ammonium chloride and Chloroquine solution in water together 
(final ceoncentration of each is 50 μM). Control cells were treated with DMSO. Cells were 
harvested at two hour time points till 16 hours post-transfection or post-induction and 
immunoblotted against anti-viperin antibody (rabbit polyclonal).  
 
Figure A7: Cellular degradation pathway involved in the cellular expression level of viperin. 
HEK293T cells expressing 3x-FLAG tagged viperin were treated with proteasomal degradation 
inhibitor MG132 (50 μM final concentration) or lysosomal degradation inhibitors Chloroquine (50 
μM) and ammonium chloride (50 μM). Blocking of lysome-mediated degradation resulted in an 
accumulation of cellular level of viperin 16 hours post-transfection.
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Appendix A8: Sinefungin and 5’deoxyadenosine reverses viperin 
mediated degradation of NS5A in vivo 
 
To examine whether viperin requires its cofactor-bound (S-adenosyl-L-methionine) active 
state to degrade NS5A in vivo, we treated HEK293T cells, expressing NS5A, VAP-33C 
and viperin/viperinΔ3C with sinefungin, a competitive inhibitor of radical SAM-dependent 
enzymes. The cells were treated with sinefungin (final concentration 45 nM) at the same 
time of transfection to allow the maximum incorporation of sinefungin in viperin and 
followed for 12 hrs before expression test. It had been shown in previous studies that 
sinefungin binds to viperin and deactivates its radical SAM activity in producing 5’-
deoxyadenosine from uncoupled reductive cleavage of SAM. Intriguingly, the sinefungin 
treated cells showed partial restoration of NS5A expression level, in presence of wild-
type viperin and VAP-33C, in comparison to the un-treated cells [Figure A8(a)]. 
Sinefungin did not show any effect on the expression level of viperin. However, intra-
cellular expression of NS5A remained similar in sinefungin treated and untreated cells, 
when co expressed with viperinΔ3C and VAP-33C [Figure A8(a)]. These results suggest 
that the SAM-bound active state of viperin might be required for its inhibitory activity 
against NS5A. 
Similar results were observed when cells, expressing NS5A, viperin and VAP-33C, were 
treated with exogenous 5’-deoxyadenosine. Reductive SAM cleavage by product 5’-
deoxyadenosine often acts as a product inhibitor for radical SAM enzymes. To
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 investigate whether 5’-deoxyadenosine can supress viperin’s ability to promote 
degradation of NS5A, we co-exoressed NS5A with viperin/viperinΔ3C and VAP-33C  in 
HEK293T cells for 12 hours, followed by treatment with exogenous 5’-deoxyadenosine 
(final concentration 5μM) for 12 hours. Consistent with the results obtained from in vivo 
sinefungin treatment assay, NS5A expression level was partially restored in presence of 
wild type viperin and VAP-33C in 5’-deoxyadenosine treated cells [Figure A8(b)], 
whereas, the protein level of NS5A remained same in 5’-deoxyadenosine-treated and 
untreated cells in presence of viperinΔ3C [Figure A8(b)]. The fact that 5’-
deoxyadenosine only inhibits viperin’s activity by competing with SAM and not by altering 
its expression level, it implies that the SAM-bound active state of wild type viperin may 
play an important role in promoting degradation of NS5A in vivo. 
 
Experimental Procedure 
Cell  HEK293T cells were obtained from ATCC. 
Materials Sinefungin (567051-2MG-M) and 5'-deoxyadenosine (D1771) were purchased 
from Sigma Aldrich. 
Treatment of cells with sinefungin and 5'-deoxyadenosine HEK293T cells and Tet 
On 3G cells were grown to 60-70% confluency and transfected with viperin/viperinΔ3C, 
NS5A and VAP-33C genes in pcDNA3.1. For sinefungin treatment, cells, sinefungin 
solution in water was added to 45 nM final concentrations at the same time of transfection 
and harvested 12 hours post transfection. For 5'-deoxyadenosine treatment, cells were 
treated with 5μM 5'-deoxyadenosine solution in water 12 hours post transfection and 
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harvested 12 hours post-treatment. Control cells were treated with water. The cells were 
lysed and immunoblotted for viperin, NS5A and VAP-33C. 
 
Figure A8. SAM-bound active state of viperin is important for NS5A degradation in vivo (a) 
HEK293T cells, transfected with genes of NS5A, FLAG-VAP-33C and viperin or viperin-Δ3C, 
were treated with Sinefungin, a competitive inhibitor of SAM at the same of transfection and 
immunoblotted 12 hours post-transfection/post-treatment. When treated with sinefungin, relative 
amount of NS5A, normalized to GAPDH were restored in presence of vipeirn and VAP-33C 
(p>0.05). However, the expression level of NS5A remain reduced in presence of mutant viperin 
(viperin-Δ3C) and VAP-33C, regardless the treatment with sinefungin. The comparisons between 
single-transfected and triple-transfected samples were executed by statistical analysis on the 
relative level of NS5A using student t-test (p1***=0.0004; p2***=0.0002; p3***=0.0017; n=10). (b) 
Similar results were observed when cells, expressing above mentioned genes were treated with 
5’-deoxyadenosine, a known product inhibitor of radical SAM enzymes. Relative amount of NS5A, 
normalized to GAPDH were partially restored in presence of vipeirn and VAP-33C  (p>0.05) when 
treated with 5’-deoxyadenosine, but not in presence of the radical SAM domain mutant viperin. 
The comparisons between single-transfected and triple-transfected samples were executed by 
statistical analysis on the relative level of NS5A using student t-test (p1***=0.0012; p2***=0.0069; 
p3***=0.0095; n=5). 
